Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
TITLE OF THE INVENTION
PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
BACKGROUND OF THE INVENT10N
Field of the Invention
The present invention relates to pyridylpyrrole derivatives, to pharmaceutical
compositions
comprising them and to their use as therapeutic agents, particularly in the
treatment of cancer
and cell proliferation. disorders.
Discussion of the Background
The malfunctioning of protein kinases (PKs) is the hallmark of numerous
diseases. A large
share of the oncogenes and proto-oncogenes involved in human cancers code for
PKs. The
enhanced activities of PKs are also implicated in many non-malignant diseases,
such as
benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-
fibromatosis, psoriasis,
vascular smooth cell proliferation associated with atherosclerosis, pulmonary
fibrosis, arthritis
glomerulonephritis and post-surgical stenosis and restenosis.
PKs are also implicated in inflammatory conditions and in the multiplication
of viruses and
parasites. PKs may also play a major role in the pathogenesis and development
of
neurodegenerative disorders.
For a general reference to PKs malfunctioning or disregulation see, for
instance, Current
Opinion in Chemical Biology 1999, 3, 459 - 465.
Among the several protein kinases known in the art as being implicated in the
growth of
cancer cells is Cdc7, an evolutionary conserved serine-threonine kinase which
plays a pivotal
role in linking cell cycle regulation to genome duplication, being essential
for the firing of DNA
replication origins (see Montagnoli A. et al., EMBO Journal, Vol. 21, No. 12,
pp. 3171-3181,
2002).
CONFIRMATION COPY
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
SUMMARY OF THE INVENTION
It is an object of the invention to provide compounds which are useful, in
therapy, as agents
against a host of diseases caused by and/or associated to a disregulated
protein kinase
activity and, more particularly, Cdk2 and Cdc7 activity.
It is another object to provide compounds, which are endowed with protein
kinase inhibiting
activity and, more particularly, Cdk2 and Cdcl inhibiting activity.
The present inventors have now discovered that some pyridylpyrroles, and
derivatives thereof,
are endowed with protein kinase inhibiting activity, e.g. Cdk2 and especially
Cdc7 inhibiting
activity.
More specifically, the compounds of this invention are useful in the treatment
of a variety of
cancers including, but not limited to: carcinoma such as bladder, breast,
colon, kidney, liver,
lung, including small cell lung cancer, esophagus, gall-bladder, ovary,
pancreas, stomach,
cervix, thyroid, prostate, and skin, including squamous cell carcinoma;
hematopoietic tumors
of lymphoid lineage, including leukemia, acute lymphocitic leukemia, acute
lymphoblastic
leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's
lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of
myeloid
lineage, including acute and chronic myelogenous leukemias, myelodysplastic
syndrome and
promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma
and
rhabdomyosarcoma; tumors of the central and peripheral nervous system,
including
astrocytoma, neuroblastoma, glioma and schwannomas; other tumors, including
melanoma,
seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum,
keratoxanthoma,
thyroid follicular cancer and Kaposi's sarcoma.
Due to the key role of PKs, Cdk2 and Cdc7 in the regulation of cellular
proliferation, these
pyridylpyrroles are also useful in the treatment of a variety of cell
proliferative disorders such
as, for instance, benign prostate hyperplasia, familial adenomatosis,
polyposis, neuro-
fibromatosis, psoriasis, vascular smooth cell proliferation associated with
atherosclerosis,
pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis
and restenosis.
The compounds of the invention can be also active as inhibitors of other
protein kinases such
as, for instance, protein kinase C in different isoforms, Met, PAK-4, PAK-5,
ZC-1, STLK-2,
2
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
DDR-2, Aurora 1, Aurora 2, Bub-1, PLK, Chk1, Chk2, HER2, raft , MEK1, MAPK,
EGF-R,
PDGF-R, FGF-R, IGF-R, VEGF-R, PI3K, weel kinase, Src, Abl, Akt, ILK, MK-2, IKK-
2, Cdk in
different isoforms, Nek, and thus be effective in the treatment of diseases
associated with
other protein kinases.
Accordingly, in a first embodiment, the present invention provides a method
for treating cell
proliferative disorders caused by and/or associated with an altered protein
kinase activity by
administering to a mammal in need thereof an effective amount of a
pyridylpyrrole derivative
represented by formula (1)
-NH
m ~ R~a
z ~ ,R~s
(I)
wherein
R~ is a hydrogen atom, amino, arylamino, C~-Cs alkylamino, C3-C~
cycloalkylamino, group, or '
an optionally substituted heterocycle group;
Rz and R'z are, each independently, a hydrogen or halogen atom or a straight
or branched C~-
Cs alkyl group; or, taken together with the pyridine bond to which they are
linked, R, and R'Z
may form a divalent -NH-CH=CH- group;
R3, R'3, R4 and R'4 are, each independently, a hydrogen atom or a group
selected from straight
or branched C~-CB alkyl, C3-C6 cycloalkyl, heterocyclyl, aryl, cycloalkyl-
alkyl, heterocyclyl-alkyl
' or aryl-alkyl; or R3 and R3 or R4 and Ra', taken together, form a C3-CB
cyclic alkyl group;
R5 is a hydrogen or halogen atom or it is a straight or branched C~-C6 alkyl
group and
pharmaceutically acceptable salts thereof.
The above method enables treatment of cell proliferative disorders caused by
and/or
associated with an altered Cdc7 kinase activity.
3
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
In a preferred embodiment of the method described above, the cell
proliferative disorder is
cancer.
Specific types of cancer that may be treated include carcinoma, squamous cell
carcinoma,
hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal
origin, tumors
of the central and peripheral nervous system, melanoma, seminoma,
teratocarcinoma,
osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular
cancer, and
Kaposi's sarcoma.
The present invention also provides a pyridylpyrrole derivative which is
represented by
formula (I)
4
wherein
R~ is a hydrogen atom, amino, arylamino, C~-Cs alkylamino, C3-C~
cycloalkylamino, group, or
IS an optionally substituted heterocycle group;
RZ and R'2 are, each independently, a hydrogen or halogen atom or a straight
or branched C~-
C6 alkyl group; or, taken together with the pyridine bond to which they are
linked, R~ and R'2
may form a divalent -NH-CH=CH- group;
Ra, R'3, Ra and R'4 are, each independently, a hydrogen atom or a group
selected from straight
or branched C~-C6 alkyl, C3-Cs cycloalkyl, heterocyclyl, aryl, cycloalkyl-
alkyl, heterocyclyl-alkyl
or aryl-alkyl; or R3 and R3'or Rd and R4', taken together, form a C3-Cs cyclic
alkyl group;
R5 is a hydrogen or halogen atom or it is a straight or branched C,-Cs alkyl
group and
pharmaceutically acceptable salts thereof.
4
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
provided that the compound is not 2-(2-aminopyridin-4-yl)-1,5,6,7-tetrahydro-
4H-pyrrolo[3,2-
cJpyridin-4-one.
A mare complete appreciation of the invention and many of the attendant
advantages thereof
will be readily obtained as the same becomes better understood by reference to
the following
detailed description.
DETAILED DESCRIPTION OF THE INVENTION
Several heterocyclic compounds are known in the art as protein kinase
inhibitors.
Among them are, for instance, pyrrolo-pyrazoles disclosed in WO 02/12242;
tetrahydroindazoles disclosed in WO 00/69846; pyrrolo-pyridines disclosed in
WO 01/98299;
aminophthalazinones disclosed in WO 03/014090 and aminoindazoles disclosed in
WO
03/02$720.
In addition, pyridylpyrrole derivatives endowed with mitogen activated protein
kinase-activated
protein kinase-2 inhibitory activity are disclosed in the published PCT
International Patent
Application WO 04/058762 (published July 15, 2004), claiming priority of U.S.
Serial No.
60/434,962, filed in December 12, 2002.
Among the compounds therein disclosed are, in particular, pyridyipyrroles
which are
substituted by aryl- or aryl-alkenyl- groups at the pyridine moiety;
pyridylpyrroles being
substituted by amino groups or halogen atoms at this same pyridine ring are
also therein
disclosed as synthetic intermediates. Among these latter intermediate
compounds are, for
instance, 2-(2-aminopyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one and 2-(2
chloropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one.
Interestingly, the compounds of the invention fall within the broad general
formula disclosed in
the aforementioned patent application US 60/434962 but are not specifically
exemplified
therein.
The compounds of formula (I) of the invention may have asymmetric carbon atoms
and may
therefore exist as individual optical isomers, as racemic admixtures or as any
other admixture
5
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
including a majority of one of the two optical isomers, which are all to be
intended as
comprised within the scope of the present invention.
Likewise, the use as an antitumor agent of all the possible isomers and their
admixtures and
of both the metabolites and the pharmaceutically acceptable bio-precursors
(otherwise
referred to as pro-drugs) of the compounds of formula (I) are also within the
scope of the
present invention.
Prodrugs are any covalently bonded compounds which release the active parent
drug,
according to formula (I), in vivo.
In cases when compounds may exist in tautomerlc forms, for instance keto-enol
tautomers,
each tautomeric form is contemplated as being included within this invention
whether existing
in equilibrium or predominantly in one form.
In the present description, unless otherwise specified, with the term straight
or branched C~-CB
alkyl we intend any of the groups such as, for instance, methyl, ethyl, n-
propyl, isopropyl, n-
butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, n-hexyl, and the like.
With the term amino we intend an -NHZ group whilst the term arylamino
comprises any
group -NH-aryl, wherein aryl is as defined below.
With the term aryl we intend any carbocyclic or heterocyclic hydrocarbon with
from 1 to 2 ring
moieties, either fused or linked to each other by single bonds, wherein at
least one of the rings
is aromatic. If present, any aromatic heterocyclic hydrocarbon also referred
to as heteroaryl
group, comprises a 5 to 6 membered ring with from 1 to 3 heteroatoms selected
among N, O
or S.
Examples of aryl groups according to the invention are, for instance, phenyl,
biphenyl, a- or ~i-
naphthyl, dihydronaphthyl, thienyl, benzothienyl, furyl, benzofuranyl,
pyrrolyl, imidazolyl,
pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl,
pyrimidinyl, pyridazinyl,
indolyl, isoindolyl, purinyl, quinolyl, isoquinolyl, dihydroquinolinyl,
quinoxalinyl, benzodioxolyl,
indanyl, indenyl, triazolyl, and the like.
6
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
With the term C3-Cs cycloalkyl we intend any group such as cyclopropyl,
cyclobutyl,
cyclopentyl and cyclohexyl.
With the term heterocyclyl we intend any 5 or 6 membered heterocyclic ring
comprising from 1
to 3 heteroatoms selected among N, 0 or S. Clearly, if the said heterocycle or
heterocyclyl
group is an aromatic heterocycle, also referred to as heteroaryl, it is
encompassed by the
above definition given to aryl groups.
As such, besides the above aromatic heterocycles, the term heterocyclyl also
encompasses
saturated or partially unsaturated heterocycles such as, for instance,
pyrroline, pyrrolidine,
imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, piperazine,
morpholine, and
the like.
From the above, it is clear to the skilled person that any group which name is
identified as a
composite name such as, for instance, cycloalkyl-alkyl, heterocyclyl-alkyl,
arylalkyl and the
like, have all to be intended as construed by the moieties from which they
derive. In this
respect, as an example, any group which is identified as an arylalkyl has to
be intended as an
alkyl group which is further substituted by aryl, wherein both aryl and alkyl
are as above
defined. Clearly when R3 and R3' or R4 and R4', taken together, form a C3-Cs
cyclic alkyl
group, the compound is referred to as spiro derivative.
When the heterocycle group is optionally substituted, the substituents are
chosen from alkyl,
haloalkyl, amino, hydroxy, alkoxy, halogen, alkoxycarbonyl, aminocarbonyl as
herein defined.
Clearly, when R, and R'Z are linked together so as to form a divalent -NH-
CH=CH- group,
fused bicyclic ring systems are obtained as having the following formula,
still being an object
of the invention:
R'~
H
R 0
5
'NH
N
N
Re
N ~ R~ R'~
Pharmaceutically acceptable salts of the compounds of formula (I) include the
acid addition
salts with inorganic or organic acids such as, for instance, nitric,
hydrochloric, hydrobromic,
sulfuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic,
glycolic, lactic, oxalic,
7
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
malonic, malic, malefic, tartaric, citric, benzoic, cinnamic, mandelic,
methanesulphonic,
isethionic and salicylic acid.
A preferred class of compounds of the invention is represented by the
derivatives of formula
(I) wherein at least one of R3 and R'3 is a hydrogen atom.
Another preferred class of compounds of the invention is represented by the
derivatives of
formula (I) wherein at least one of R4 and R'4 is a hydrogen atom.
Still more preferred compounds of the invention, within the above classes, are
the derivatives
of formula (I) wherein R,, R2 and R'Z are, each independently, hydrogen or
halogen atoms and
R5 is a hydrogen atom or a methyl group.
For a reference to any specific compound of formula (I) of the invention,
optionally in the form
of a pharmaceutically acceptable salt, see the experimental section and
claims.
The compounds of formula (I) and the pharmaceutically acceptable salts thereof
may be
obtained by a process comprising:
a) reacting the Meldrum's acid of formula (II) with a suitable aminoacid
derivative of
formula (III) so as to obtain a compound of formula (IV)
O O R3 Rr3 0 0 Me
Q~N O H ~ R'3 ~Me
0 ,N / O
Ra R'a OH Q
O Re R~a OH O
(11) (III) (IV)
wherein Q is a suitable nitrogen protecting group, most preferably a t-
butoxycarbonyl (Boc),
and R3, R'3, R4 and R'4 are as above defined;
b) heating the compound of formula (IV) in the presence of ethanol so as to
obtain a
compound of formula (V).
8
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
R3 R'3
H
~N OEt
Q
Ra R~e O 0
(V)
c) reacting the compound of formula (V) with a pyridine derivative of formula
(VI) and
treating the resulting intermediate with ammonium acetate, so as to obtain a
compound of
formula (VII)
Rz Rz Rs O
O
N ~ ~ ~ / ~ DOE
~ N
?-Hal
H R'~
R~ R~z Rs R~ R~z R4
(V~) (~~) R,~ i H
Q
wherein R~, RZ, R3, R'3, R4 , R'4 are as above defined, R5 is a hydrogen atom
or a straight or
branched Ci-Cs alkyl group, Q is the aforementioned nitrogen protecting group
and Hal
represents a suitable halogen atom;
d) deprotecting the compound of formula (VII) by removing the Q group in a
suitable
manner, e.g. by acidic treatment when Q is t-butoxy carbonyl so as to obtain a
compound of
formula (VIII)
(VIII)
e) refluxing the compound of formula (VIII) in the presence of a base so as to
obtain the
desired compound of formula (I) and, optionally, converting it into another
compound of
formula (I) and/or into a pharmaceutically acceptable salt thereof.
9
R, mn3r
4
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
In alternative, the product (V) may be synthesized reacting the aminoacid
derivative of formula
(III) with ethyl potassium malonate in the presence of 1,1'-
carbonyldiimidazole and magnesium
chloride.
The above process is an analogy process which can be carried out according to
methods well
known in the art.
According to step (a) of the process, the Meldrum's acid of formula (i1) is
reacted with the
aminoacid derivative of formula (III) in the presence of a base, for instance
dimethylaminopyridine (DMAP), and of a suitable solvent such as
dichloromethane (DCM).
The reaction is carried out in the presence of a carbodiimide such as N,N'-
dicyclohexylcarbodiimide at a temperature of about 0°C and for a time
varying from about 2
hours to about 24 hours.
According to step (b) of the process, the crude material of formula (IV) being
obtained in step
(a) is dissolved in ethanol and heated at a temperature ranging from about
50°C to refluxing
temperature, for a time of about 2 hours to about 12 hours, thus affording the
compound of
formula (V).
In the alternative route to obtain the compound of formula (V), the compound
of formula (III) is
reacted with potassium malonate in the presence of 1,1'-carbonyldiimidazole
and magnesium
chloride. In this instance, to a solution of (III), in anhydrous
tetrahydrofuran (THF), 1,1'-
carbonyldiimidazole is added; the solution is left shaking 2 hours and ethyl
potassium
malonate and magnesium chloride are added. The temperature is then brought to
a suitable
value, that is, from 40 to 60 °C. Preferred is 45 °C. Stirring
is carried out for a suitable time
from 4 to 18 h.
According to step (c) of the process, the compound of formula (V) is reacted
with a suitable
pyridine derivative of formula (VI), in the presence of sodium hydride and,
successively, of
ammonium acetate, in a suitable solvent such as, for instance, tetrahydrofuran
so as to obtain
a compound of formula (VII). Preferably, within the compounds of formula (VI),
Hal represents
a bromine or chlorine atom. In this instance to a solution of (V) in dry THF,
sodium hydride is
added; stirring is carried out for 30 min and a suitable pyridine derivative
(VI) is added. The
reaction is carried out at a temperature of about 0°C and for a time
varying from about 1 hour
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
to about 6 hours. To the crude material obtained ammonium acetate in ethanol
is added.
Stirring at room temperature is carried out for a suitable time from 5 to 24
hours.
The thus obtained compound of formula (VII) is then deprotected at the
nitrogen atom, in step
(d) of the process, through acidic treatment, so as to obtain the
corresponding amino
derivative of formula (VIII) in the form of an acid addition salt.
The reaction is carried out according to conventional methods in the presence
of a suitable
acid such as, for instance, hydrochloric or tritluoroacetic acid and of a
suitable solvent, for
instance, tetrahydrofuran, dioxane or the like. Stirring at room temperature
is maintained for a
suitable period of time.
According to step (e) of the process, the compound of formula (VIII) is then
converted into the
desired compound of formula (I) by treatment with a base, for instance sodium
carbonate, in
the presence of a lower alcohol such as ethanol. The reaction is carried out
at refluxing
temperature for a time varying from about 12 hours to about 24-48 hours.
The compounds of formula (II), (Ill) and (VI), as well as any other reactant
of the process, are
known or, if not commercially available per se, they can be easily prepared
according to
known methods.
As an example, the pyridine derivatives of formula (VI) may be prepared by
halogenating, e.g.
brominating or chlorinating, a suitable pyridine-ethanone derivative,
according to the following
pathway:
RZ R2
halogenation
N ~ N
Rs Hal
R~ R~z . R~ R~z Rs
(v1)
The reaction occurs by working under conventional methods, for instance in the
presence of
bromine and in a suitable solvent such as a mixture of acetic and
hydrobromic,acid, for a time
varying between about 1 hour and about 24 hours. Alternatively, a suitably
activated pyridine
derivative, e.g. an enolether or silylether, can be reacted with a halogen
source, for instance
11
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
N-bromo-succinimide (NBS), in a suitable solvent, such as
tetrahydrofuran/water mixtures.
Among the suitable pyridine-ethanone derivatives subdued to halogenation we
consider, for
instance, 1-pyridin-4-ylethanone, 1-pyridin-4-ylpropan-1-one, the intermediate
1-(2-
chloropyridin-4-yl)ethanone and 1-(3-fluoropyridin-4-yl)ethanone.
S
1-(2-Chloropyridin-4-yl)ethanone can be easily prepared according to well
known methods, for
example reacting commercial 2-chloroisonicotinonitrile with a methylmagnesium
halide. 1-(3-
Fluoropyridin-4-yl)ethanone can be prepared, for example, by reacting
commercial 3-
fluoropyridine with acetaldehyde in the presence of a base, such as, for
example,
lithiumdiisopropylamide (LDA) and oxidizing the so obtained 1-(3-tluoropyridin-
4-yl)ethanol by
means of, for instance, manganese dioxide in a suitable solvent, like toluene.
In addition, the compounds of formula (V!) wherein R~ and R'Z are linked
together so as to
form a -NH-CH=CH- group, may be also prepared according to conventional
methods by
starting from known 4-chloro-1H-pyrrole[2,3-bJpyridine, according to the
following scheme:
\'OEt OEt
CI C ~I
SnBu3 I \
DMAP, CHIC N N Pd(PPh3)4, DMF N N
O/~0-tBu ~0-teu
O
'Br
NBS
THF water ~ N
N H
VI
4-Chloro-1H-pyrrole(2,3-b]pyridine is first protected, at the pyrrole nitrogen
atom, as tert-
butoxycarbonyl derivative (Boc) according to known methods, in the presence of
dimethylaminopyridine and in a suitable solvent like acetonitrile. The
obtained compound is
then reacted with 1-(ethoxyvinyl)tributyltin, in the presence of palladium
tetrakis
triphenylphosphine and in dimethylformamide, so as to obtain the corresponding
ethoxyvinyl
derivative which, subsequently, is reacted with N-bromosuccinimide in the
presence of a
tetrahydrofuran/water mixture, so as to get the desired compound.
2S
12
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
According to an alternative approach, the compounds of formula (I) may be also
prepared
according to the following synthetic scheme, by reacting the above pyridine
derivative of
formula (VI) with a suitable piperidine-dione derivative of formula (IX)
wherein Q is H or the
aforementioned nitrogen protecting group, preferably tent-butoxycarbonyl or p-
methoxybenzyl,
p-methoxyethylbenzyl, p-methoxyphenyl group.
0
~Q
'N
R~a
R
R~ R'3 4
N / \ (IX)
..
'4
Rt Rz, Rs
NI) (x>
The reaction occurs in the presence of ammonium acetate and of a suitable
solvent such as,
for instance, a lower alcohol. Preferably, the reaction is carried out in the
presence of ethanol
by working at room temperature and for a suitable time varying from about 2
hours to about 24
hours. Optionally compound (X) can be converted into compound (I) by removal
of the
protecting group Q.
With this approach also compounds of formula (I), where R1 is an alkylamino or
cycloalkyl
amino group or an heterocycie, have been prepared starting from an
intermediate of formula
(X), where R1 is chloro, which was reacted with the appropriate amine or
heterocycle in the
presence or in the absence of a suitable solvent, but mope often without
solvents, and the
reaction was usually carried out at temperatutes ranging from 100 to
300°C for 0.1 to 12
hours, optionally inside a microwave cavity.
Also the piperidine-dione derivative (IX) is a known compound or,
alternatively, can be
prepared by known methods, for instance according to the synthetic pathway
below, wherein
Alk stands for a suitable lower alkyl group, e.g. ethyl, and A stands for
chloro or OAIk:
13
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
O 0
R4 R1~ O Ra R4
~~~ A' v _OAIk '~~~
~ ~
AIkO NH O
~ AIkO
NH2 ~
R~ R 5 R~ R'3 %~
(x~) O O OAIk
t) base, ~Q (X11)
0
2) D R,e
O
3) protectionRa
R~ R'~
(IX)
!n this respect, a suitable ~i-amino-carboxyester (XI) derivative wherein R3,
R'3, R4 and R'4
have the above reported meanings, is reacted with dialkylmalonate or,
alternatively, with 3-
chloro-3-oxopropanoic acid alkyl ester, for instance, dimethylmalonate or
ethyl 3-chloro-3-
oxopropanoate, respectively. When A is chloro the reaction is carried out
under basic
conditions, for instance in the presence of triethylamine, and in a suitable
solvent such as
dichloromethane, at a temperature comprised between room temperature to
reflux. When A is
OAIk the reaction is carried out with or without basic cond(tions and more
conveniently in the
absence of solvents at refiux temperature of the dialkylmalonate.
When not commercially available, the above mentioned ~3-amino-carboxyester
derivatives can
be obtained according to well known procedures described in the literature.
The intermediate derivative thus obtained (X11) is then converted into the
compound of formula
(IX) in a two-steps reaction, by first reacting it under basic conditions,
e.g. in the presence of
sodium methylate and of a suitable solvent, preferably toluene, at refluxing
temperature and
for a time varying between about 2 hours and about 24 hours. Subsequently, the
product of
the former step is reacted as such, without being isolated, with an
acetonitrile/water/acetic
acid mixture under refluxing conditions and for a time varying between about
12 hours and
about 24 hours. Optionally the piperidin-dione (IX) can be protected with a
suitable protecting
group Q.
In the alternative, the piperidine-dione derivative (IX) can be prepared, for
instance, according
also to the alternative synthetic pathway below:
14
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
O OH 0
Rn R~n
O
w
R4 R'4 /Q (II) 0 ~ NH 0 N~f
/v
HO~~~~ N I
H Rs R~~ Q
R'3 ~O O O R4
Ra R~a
(III) (IV) (IX)
In the procedure the Meldrum's acid of formula (II) is reacted with a suitable
aminoacid
derivative of formula (11I) so as to obtain a compound of formula (IV) wherein
Q is a suitable
nitrogen protecting group and R3, R'3, R4 and R'4 are as above defined. The
compound of
formula (IV) is then cyclized by dissolving it in a suitable solvent, for
instance ethylacetate, and
refluxing for a period of time from 1 to 24 hours;
or, in the alternative, the piperidine-dione derivative (IX) can be modified
according to the
synthetic pathway below, wherein Q stands for a suitable nitrogen-protecting
group such as, in
particular, tert-butoxycarbonyl, or other groups, such as p-methoxybenzyl, p-
methoxyethylbenzyl, p-methoxyphenyl:
0 0 0
~O ~O NH
~N 1) base ~N deprotect(on
R~< 2) R'3X R', R~a
O Rs H Ra 0 Ra R.s Re O Ra R~a Ra
(IX) (IX) (IX)
In this respect, a suitable piperidine-dione derivative (IX) wherein F~, R4
and R'4 and Q have
the above reported meanings, is reacted with a base, for instance lithium
bis(trirnethylsilyl)amide (LiHMDS). The reaction is carried out in a suitable
solvent such as
tetrahydrofuran, at a temperature comprised between -78°C and room
temperature.
The reaction mixture is then treated with a suitable alkyl halide thus
obtaining another
compound of formula (IX). The compound thus obtained, where Q is for instance
a tert-
butoxycarbonyl group, can be converted into another compound of formula (IX)
by treating it
with acidic conditions, e.g. in the presence of trifluoroacetic acid and of a
suitable solvent,
preferably dichloromethane, at room temperature and for a time comprised
between about 1
hours and about 6 hours.
15
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
The final compound of formula (I) thus obtained may be then converted into
another
compound of formula (I) according to well-known methods in the art. As an
example, the
compounds of formula (I) wherein RS represents a hydrogen atom can be easily
converted into
the corresponding compounds of formula (I) wherein R5 is a halogen atom,
through
conventional methods reported in the literature for the halogenation of
pyrrole derivatives.
Likewise, the conversion of a compound of formula (t) into a pharmaceutically
acceptable salt
is easily carried out according to known methods, e.g. by contacting any free
base of formula
(I) with any suitable pharmaceutically acceptable acid.
From all of the above, it is clear to the skilled person that when preparing
the compounds of
formula (I) according to the aforementioned processes, comprehensive of any
variant thereof,
optional functional groups within the starting materials or the intermediates
thereof and which
could give rise to unwanted side reactions, need to be properly protected
according to
conventional techniques. Likewise, the conversion of these latter into the
free deprotected
compounds may be carried out according to known procedures.
By analogy, any compound of formula (1) which is susceptible of being salitied
can be easily
converted into the corresponding acid addition salt, by working in the
presence of any
pharmaceutically acceptable acid, for instance selected among those previously
reported.
As it will be readily appreciated, if the compounds of formula (I) prepared
according to the
process described above are obtained as a mixture of isomers, their separation
into the single
isomers of formula (I), according to conventional techniques, is also within
the scope of the
present invention.
Conventional techniques for racemate resolution include, for instance,
partitioned
crystallization of diastereoisomeric salt derivatives or preparative chiral
HPLC.
PHARMACOLOGY
The compounds of formula (I) are active as protein kinase inhibitors and are
therefore useful,
for instance, to restrict the unregulated proliferation of tumor cells.
in therapy, they may be used in the treatment of various tumors, such as those
formerly
reported, as well as in the treatment of other cell proliferative disorders
such as psoriasis,
16
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
vascular smooth cell proliferation associated with atherosclerosis and post-
surgical stenosis
and restenosis and in the treatment of Alzheimer's disease.
The inhibiting activity of putative Cdc7 inhibitors and the potency of
selected compounds is
determined through a method of assay based on the use of Dowex resin capture
technology.
The assay consists of the transfer of radioactivity labeled phosphate moiety
by the kinase to
an acceptor substrate. The resulting 33P-labeled product is separated from
unreacted tracer,
transferred into a scintillation cocktail and light emitted is measured in a
scintillation counter.
Inhibition assay of Cdc7IDbf4 activity
The inhibition assay of Cdc7/Dbf4 activity is performed according to the
following protocol.
The MCM2 substrate is trans-phosphorylated by the Cdc7/Dbf4 complex in the
presence of
ATP traced with y33-ATP. The reaction is stopped by addition of Dowex resin in
the presence
of formic acid. Dowex resin particles capture unreacted r33-ATP and drag it to
the bottom of
IS the well while 33P phosphorylated MCM2 substrate remains in solution. The
supernatant is
collected, transferred into Optiplate plates and the extent of substrate
phosphorylation is
evaluated by p counting.
The inhibition assay of Cdc7/Dbf4 activity was performed in 96 wells plate
according to the
following protocol.
To each well of the plate were added:
- 10 NI test compound (10 increasing concentrations in the nM to NM range to
generate a
dose-response curve). The solvent for test compounds contained 3% DMSO. (final
concentration 1 %)
- 10 NI substrate MCM2 (6 NM final concentration), a mixture of cold ATP (2 NM
final
concentration) and radioactive ATP (1/5000 molar ratio with cold ATP).
- 10 NI enzyme (Cdc7/Dbf4, 2 nM final concentration) that started the
reaction. The buffer of
the reaction consisted in 50 mM HEPES pH 7.9 containing 15 mM MgCl2, 2 mM
D'1T, 3
pM NaV03, 2mM glycerophosphate and 0.2mg/ml BSA.
17
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
After incubation for 60 minutes at room temperature, the reaction was stopped
by adding to
each well 150 NI of Dowex resin in the presence of 150 mM formic acid. After
another 60 min
incubation, 50 NL of suspension were withdrawn and transferred into 96-well
OPTIPLATEs
containing 150 NI of MicroScint 40 (Packard); after 5-10 minutes shaking the
plates were read
for 1 min in a Packard TOP-Count radioactivity reader.
1C50 determination: inhibitors were tested at different concentrations ranging
from 0.0005 to
NM. Experimental data were analyzed by the computer program Assay Explorer
using the
four parameter logistic equation:
y = bottom+(top-bottom)/(1+10~((IogIC50-x)*slope))
where x is the logarithm of the inhibitor concentration, y is the response; y
starts at bottom and
goes to top with a sigmoid shape.
The Inhibiting activity of putative cdk/cyclin inhibitors and the potency of
selected compounds
may be determined through a method of assay based on the use of the SPA
technology
(Amersham Pharmacia Biotech).
The assay consists of the transfer of radioactivity labelled phosphate moiety
by the kinase to a
biotinylated substrate. The resulting 33P-labelled biotinylated product is
allowed to bind to
streptavidin-coated SPA beads (biotin capacity 130 pmol/mg), and Ilght emitted
was measured
in a scintillation counter.
Inhibition assay of cdk2lCyclin A activity
Kinase reaction: 4 NM in house biotinylated histone H1 (Sigma # H-5505)
substrate, 10 NM
ATP (0.1 microCi P33y-ATP), 1.1 nM Cyclin A/CDK2 complex, inhibitor in a final
volume of 30
u1 buffer (TRIS HCI 10 mM pH 7.5, MgCl2 10 mM, DTT 7.5 mM + 0.2 mg/ml BSA)
were added
to each well of a 96 U bottom. After incubation for 60 min at room
temperature, the reaction
was stopped by addition of 100 N I PBS buffer containing 32 mM EDTA, 500 pM
cold ATP,
0.1 % Triton X100 and 10mg/ml streptavidin coated SPA beads. After 20 min
incubation, 110
pL of suspension were withdrawn and transferred into 96-well OPTIPLATEs
containing 100 NI
of 5M CsCI. After 4 hours, the plates were read for 2 min in a Packard TOP-
Count radioactivity
reader.
18
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
IC50 determination: inhibitors were tested at different concentrations ranging
from 0.0015 to
IrM. Experimental data were analyzed by the computer program GraphPad Prizm
using the
four parameter logistic equation:
5 y = bottom+(top-bottom)/(1+10~((IogIC50-x)*slope))
where x is the logarithm of the inhibitor concentration, y is the response; y
starts at bottom and
goes to top with a sigmoid shape.
10 Ki calculation:
Experimental method: Reaction was carried out in buffer (10 mM Tris, pH 7.5,
10 mM MgCl2,
0.2 mg/ml BSA, 7.5 mM DTT) containing 3.7 nM enzyme, histone and ATP (constant
ratio of
cold/labeled ATP 1/3000). Reaction was stopped with EDTA and the substrate
captured on
phosphomembrane (Multiscreen 96 well plates from Millipore). After extensive
washing, the
multiscreen plates were read on a top counter. Control (time zero) for each
ATP and histone
concentrations was measured.
Experimental design: Reaction velocities are measured at four ATP, substrate
(histone) and
inhibitor concentrations. An 80-point concentration matrix was designed around
the respective
ATP and substrate Km values, and the inhibitor IC50 values (0.3, 1, 3, 9 fold
the Km or IC50
values). A preliminary time course experiment in the absence of inhibitor and
at the different
ATP and substrate concentrations allows the selection of a single endpoint
time (10 min) in
the linear range of the reaction for the Ki determination experiment.
Kinetic parameter estimates: Kinetic parameters were estimated by simultaneous
nonlinear
least-square regression using [Eq.1] (competitive inhibitor respect to ATP,
random
mechanism) using the complete data set (80 points):
_ Vm~A~B
Ka B lEq.1]
a~Ka~Kb+a~.h'a~B+a~Kb~A+A~B+a~-~1~(Kb+-)
Ki
19
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
where A=[ATP], B=[Substrate], I~[nhibitor], Vm= maximum velocity, Ka, Kb, iG
the
dissociation constants of ATP, substrate and inhibitor respectively, a and [i
the cooperativity
factor between substrate and ATP binding arid substrate and inhibitor binding
respectively.
As an example, some representative compounds of the invention were tested as
formerly
reported against Cdc71Dbf4 or Cdk2, showing an inhibitory activity, expressed
as IC50 (nM),
as follows:
2-(1 H-pyrrolo[2,3-b]pyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
hydrochloride IC50 Cdc7: 16nM;
2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-oneCdc7:
hydrochloride IC50
7nM;
2-(3-fluoropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-oneICSO
hydrochloride
Cdc7: 8nM;
3-methyl-2-pyridin-4-yt-1,5,6,7-tetrahydro-4H-pyrroloj3,2-c]pyridin-4-oneIC50
hydrochloride
Cdc7: 3nM;
2-(1 H-pyrrolo[2,3-b]pyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrofoj3,2-c]pyridin-
4-one
hydrochloride IC50 Cdc7: 16nM;
(6S)-6-methyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-
oneCdc7:
IC50
l4nM;
(6R,6S)-6-benzyl-2-pyridin-4-yi-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-
oneCdc7:
ICSO
16nM;
(6R or 6S)-6-benzyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-0ne IC50
Cdc7: 20nM;
(6R or 6S)-6-benzyl-2-pyridin-4-yl-1,5,6,7-tefrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
IC50 Cdc7: 9nM;
(6R,6S)-6-(2-phenylethyl~2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrroto[3,2-
c]pyridin-4-one
hydrochloride IC50 Cdc7: 26nM;
(7R, 7S)-7-methyl-2-pyridin-4-yl-1, 5,6, 7-tetra hydra-4H-pyrroloj3, 2-
c]pyridin-4-one
hydrochloride IC50 Cdc7: 5nM;
(7R or 7S)- 7-methyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-
c]pyridin-4-one
IC50 Cdc7: 4nM;
(7R or 7S)- 7-methyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-
c]pyridin-4-one
IC50 Cdc7: 7nM;
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
(6R,6S)-6-isopropyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
hydrochloride IC50 Cdc7: 9nM;
(7R,7S)-7-benzyl-2-pyridin-4-yl-1, 5,6,7-tetrahydro-4H-pyrrofo[3,2-c]pyridin-4-
one
IC50 Cdc7: 17nM;
(6R,6S}-6-cyclopropyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-
c)pyridin-4-one
IC50 Cdc7: 2nM;
(6R, 6S)-6-cyclohexyl-2-pyridin-4-yl-1, 5,6, 7-tetrahydro-4H-pyrrolo[3,2-
c]pyridin-4-one
IC50 Cdc7: 8nM;
(7R,75)-7-isopropyl-2-pyridin-4-yl-1,5,6, 7-tetrahydro-4H-pyrrolo[3,2-
c]pyridin-4-one
IC50 Cdc7: 20nM;
(7R,7S)-7-sec-butyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
IC50 Cdc7: 3nM;
2'-pyridin-4-yl-5',6'-dihydrospiro[cyclopropane-1,T-pyrrolo[3,2-c]pyrldin]-
4'(1'H)-on 1C50 Cdc7:
2nM;
(7R,7S)-7-isobutyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
hydrochloride IC50 Cdc7: 5nM;
(7R,7S)-7-ethyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c)pyridin-4-
one
hydrochloride (C50 Cdc7: 2nM;
7,7-dimethyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
hydrochloride
IC50 Cdc7: 3nM;
7,7-diethyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
hydrochloride
IC50 Cdc7: 7nM;
(7R,75)-2-(3-fluoropyridin-4-yl)-7-isopropyl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-
c)pyridin-4-one
IC50 Cdc7: 3nM;
(7R,7S)-2-(3-fluoropyridin-4-yl)-7-isobutyl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-
c]pyridin-4-one
IC50 Cdc7: 4nM;
(7R,7S)-2-(3-fluoropyridin-4-yl)-7-ethyl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-
c]pyridin-4-one
IC50 Cdc7: 1 nM and
2-[2-(cyclopentylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-
c]pyridin-4-one
IC50 Cdk2: 40nM.
The compounds of the present invention can be administered either as single
agents or,
alternatively, in combination with known anticancer treatments such as
radiation therapy or
chemotherapy regimen in combination with cytostatic or cytotoxic agents,
antibiotic-type
21
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
agents, alkylating agents, antimetabolite agents, hormonal agents,
immunological agents,
interferon-type agents, cyclooxygenase inhibitors (e.g. COx-2 inhibitors),
matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase
inhibitors, anti-growth
factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis
agents (e.g.
angiogenesis inhibitors), farnesyl transferase inhibitors, ras-raf signal
transduction pathway
inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding
agents, topoisomerase I
inhibitors, topoisomerase II inhibitors, and the like.
If formulated as a fixed dose, such combination products employ the compounds
of this
invention within the dosage range described below and the other
pharmaceutically active
agent within the approved dosage range.
Compounds of formula (I) may be used sequentially with known anticancer agents
when a
combination formulation is inappropriate.
The compounds of formula (I) of the present invention, suitable for
administration to a
mammal, e.g., to humans, can be administered by the usual routes and the
dosage level
depends upon the age, weight, conditions of the patient and administration
route.
For example, a suitable dosage adopted for oral administration of a compound
of formula (I)
may range from about 10 to about 500 mg per dose, from 1 to 5 times daily. The
compounds
of the invention can be administered in a variety of dosage forms, e.g.,
orally, in the form
tablets, capsules, sugar or film coated tablets, liquid solutions or
suspensions; rectally in the
form suppositories; parenterally, e.g., intramuscularly, or through
intravenous and/or
intrathecal and/or intraspinal injection or infusion.
The present invention also includes pharmaceutical compositions comprising a
compound of
formula (I) or a pharmaceutically acceptable salt thereof in association with
a pharmaceutically
acceptable excipient, which may be a carrier or a diluent.
The pharmaceutical compositions containing the compounds of the invention are
usually
prepared following conventional methods and are administered in a suitable
pharmaceutical
form.
22
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
For example, the solid oral forms may contain, together with the active
compound, diluents,
e.g., lactose, dextrose saccharose, sucrose, cellulose, corn starch or potato
starch; lubricants,
e.g., silica, talc, stearic acid, magnesium or calcium stearate, and/or
polyethylene glycols;
binding agents; e.g., starches, arabic gum, gelatine methylcellulose,
carboxymethylcellulose
or polyvinyl pyrrolidone; disintegrating agents, e.g., starch, alginic acid,
alginates or sodium
starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents
such as lecithin,
polysorbates, laurylsulphates; and, in general, non-toxic and
pharmacologically inactive
substances used in pharmaceutical formulations. These pharmaceutical
preparations may be
manufactured in known manner, for example, by means of mixing, granulating,
tabletting,
sugar-coating, or film-coating processes.
The liquid dispersions for oral administration may be, e.g., syrups, emulsions
and
suspensions.
As an example, the syrups may contain, as carrier, saccharose or saccharose
with glycerine
and/or mannitol and sorbitol.
The suspensions and the emulsions may contain, as examples of carriers,
natural gum, agar,
sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl
alcohol.
The suspension or solutions far intramuscular injections may contain, together
with the active
compound, a pharmaceutically acceptable carrier, e.g., sterile water, olive
oil, ethyl oleate,
glycols, e.g., propylene glycol and, if desired, a suitable amount of
lidocaine hydrochloride.
The solutions for intravenous injections or infusions may contain, as a
carrier, sterile water or
preferably they may be in the form of sterile, aqueous, isotonic, saline
solutions or they may
contain propylene glycol as a carrier.
The suppositories may contain, together with the active compound, a
pharmaceutically
acceptable carrier, e.g., cocoa butter, polyethylene glycol, a polyoxyethylene
sorbitan fatty
acid ester surfactant or lecithin.
With the aim to better illustrate the present invention, without posing any
limitation to it, the
following examples are now given.
23
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
General methods
Flash Chromatography was performed on silica gel (Merck grade 9395, 60A). HPLC
was
performed on Waters X Terra RP 18 (4,6 x 50 mm, 3.5 Nm) column using a Waters
2790
HPLC system equipped with a 996 Waters PDA detector and Micromass mod. ZQ
single
quadrupole mass spectrometer, equipped with an electrospray (ESI) ion source.
Mobile phase
A was ammonium acetate 5 mM buffer (pH 5.5 with acetic acid/acetonitrile
95:5), and Mobile
phase B was H20/acetonitrile (5:95). Gradient from 10 to 90% B in 8 minutes,
hold 90% B 2
minutes. UV detection at 220 nm and 254 nm. Flow rate 1 mUmin. Injection
volume 10 NI. Full
scan, mass range from 100 to 800 amu. Capillary voltage was 2.5 KV; source
temp. was
120°C; cone was 10 V. Retention times (HPLC r.t.) are given in minutes
at 220 nm or at 254
nm. Mass are given as m/z ratio.
When necessary, compounds have been purified by preparative HPLC on a Waters
Symmetry
C18 (19 x 50 mm, 5 um) column using a Waters preparative HPLC 600 equipped
with a 996
Waters PDA detector and a Micromass mod. ZMD single quadrupole mass
spectrometer,
electron spray ionization, positive mode. Mobile phase A was water 0.01 % TFA,
and Mobile
phase B was acetonitrile. Gradient from 10 to 90% B in 8 min, hold 90% B 2
min. Flow rate 20
rnllmin.
1 H-NMR spectrometry was performed on a Mercury VX 400 operating at 400.45 MHZ
equipped with a 5 mm double resonance probe [1 H (15N-31 P) ID PFG Varian].
The compounds of formula (I), having an asymmetric carbon atom and obtained as
racemic
mixture, were resolved by HPLC separation on chiral columns. In particular,
for example,
preparative columns CHIRALPACK~ AD, CHIRALPACK~ AS, CHIRALCELL~ OJ can be
used.
Example 1
DL-3-[(tert-butoxycarbonyl)arninol4-phenylbutanoic acid
2 g (11.17 mmol) of DL-3-amino-4-phenylbutanoic acid were dissolved in 50 mL
of
dioxane/water 1:1 and 2,3 mL of triethylamine were added. The mixture was
cooled to 0°C
and 2.7 g (12.38 mmol) of di-tert-butyl Bicarbonate were added. The solution
was left at room
temperature overnight. The suspension was partially dried and extracted with
ethyl acetate
24
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
and water. The aqueous extract was acidified with 5% NaHSOa and then extracted
with AcOEt
three times. The organic extracts were dried over sodium sulfate and the
solvent evaporated
undervacuum.
About 2.5 g of DL-3-[(tart-butoxycarbonyl)amino]-4-phenylbutanoic acid were
recovered.
H~NMR (300 MHz, CDCI3) b ppm 1.33 (s, 9H), 2.25-2.32 (m, 2H), 2.65 (d, 2H),
3.83-3.96 (m,
1 H), 6.77 d(d, 1 H), 7.12-7.3 (m, 5H) .
By working in an analogous way and by starting from the corresponding DL-beta
aminoacid
derivatives the following products were synthesized:
DL-3-[(tart-butoxycarbonyl)amino]-3-cyclopropylpropanoic acid
1 H NMR (300 MHz, DMSO-D6) 8 ppm -0.04 - 0.46 (m, 4 H) 0.76 - 0.97 (m, 1 H)
1.35 (s, 9 H)
2.39 (d, J=6.15 Hz, 2 H) 6.71 (d, J=9.08 Hz, 1 H) 12.04 (s, 1 H)
[M+H]+= 230
DL-3-Lert-butoxycarbonyl]lamino]-3-cyctohex r~l ~rapanoic acid
1 H NMR (300 MHz, DMSO-D6) i5 ppm 0.78 -1.77 (m, 20 H) 2.13 - 2.41 (m, 2 H)
3.52 - 3.70
(m, 1 H) 6.58 (d, J=9.38 Hz, 1 H) 11.99 (s, 1 H)
ESI (+) MS: m/z 272 (MH+).
DL-3 j(tart-butoxycarbony~aminoj-2-methyipropanoic acid
ESl (+) MS: m/z 204 (MH+).
DL-3-[(tart-butoxycarbanyl)amino]-4-methylpentanoic acid
ESI (+) MS: m/z 232 (MH+).
DL-3-[(tart-butoxycarbonyl)amino -4-phenylbutanoic acid
ESI (+) MS: m/z 280 (MH+).
Example 2
Pr~aration of ethyl 5-[(tart-butoxycarbonyl)amino -3-oxopentanoate
1.26 g (6.6 mmol) of N-Boc-beta-alanine were dissolved with 1 g of Meldrum's
acid (6.9 mmol)
and 1.28 g (10.49 mmol) of 4-dimethylaminopyridine in 70 ml of dichloromethane
(DCM). The
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
reaction mixture was cooled to 0°C and a solution of 1.58 g (7.67 mmol)
of N,N'-
dicyclohexylcarbodiimide in 50 mL of DCM was added dropwise. The mixture was
left at 0°C
overnight, during which time tiny crystals of dicyclohexylurea precipitated.
After filtration, the
reaction mixture was washed 3 times with an aqueous solution of 5% sodium
bisulfate and
S one more time with brine. Organic extracts were dried over sodium sulfate
and the solvent
was evaporated under vacuum and then dried.
The solid was dissolved in ethanol and heated at 70°C for 6 hours. The
solvent was removed
and the raw product was purified by flash chromatography over silica gel thus
obtaining 650
mg of the title compound as a yellow oil.
H'NMR (300 MWz, CDCI3); S ppm 1.27 (t, 3H), 1.4 (s, 9H), 2.78 (t, 2H), 3.36
(m, 2H), 3.44 (s,
2H), 4.2 (q, 2H), 5.0 (br. s., 1 H).
By working in an analogous way and by starting from (3S)-3-[(tert-
butoxycarbonyl)amino]butanoic acid, the following compound was prepared:
ethyl (5S)-5-((tert-butoxycarbonyl)amino]-3-oxohexanoate
1 H NMR (400 MHz, DMSO-D6) b ppm 1.03 (d, J=6.58 Hz, 3 H) 1.20 (t, J=7.13 Hz,
3 H) 1.38
(s, 9 H) 2.53 - 2.75 (m, 2 H) 3.58 (s, 2 H) 3.78 - 3.93 (m, 1 H) 4.10 (q,
J=7.07 Hz, 2 H) 6.77 (d,
J=7.80 Hz, 1 H).
By working in an analogous way and by starting from (3S)-3-[(tert-
butoxycarbonyl)amino]-3-
phenylpropanoic acid, the following compound was prepared:
ethyl (5S)-5-((tert-butoxycarbonyl)amino]-3-oxo-5-phenylpentanoate
1 H NMR (400 MHz, DMSO-D6) 8 ppm 1.18 (t, J=7.13 Hz, 3 H) 1.36 (s, 9 H) 2.83 -
3.05 (m, 2
H) 3.59 (s, 2 H) 4.09 (q, J=7.07 Hz, 2 H) 4.89 - 4.99 (m, 1 W) 7.16 - 7.43 (m,
6 H)
By working in an analogous way and by starting from (3R)-3-[(tert-
butoxycarbonyl)amino]-4-
methylpentanoic acid, the following compound was prepared:
26
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
ethyl (5R)-5-[(tart-butoxycarbonyl)amino]-6-methyl-3-oxoheptanoate
1 H NMR (400 MHz, DMSO-D6) b ppm 0.8 (d, 6 H) 1.20 (t, J=7.13 Hz, 3 H) 1.38
(s, 9 H) 1.61 -
1.72 (m, 1 H) 2.60 - 2.70 (m, 2 H) 3.59 (s, 2 H) 3.67 - 3.77 (m, 1 H) 4.10 (q,
J=7.07 Hz, 2 H)
6.68 (d, J=8.78 Hz, 1 H)
By working in an analogous way and by starting from DL-3-[(tert-
butoxycarbonyl)amino]-4-
phenylbutanoic acid the following compound was prepared:
ethyl 5-((tert-butoxycarbonyl)amino]-3-oxo-6-phenylhexanoate
1 H NMR (400 MHz, DMSO-D6) b ppm 1.18 (t, J=7.13 Hz, 3 H) 1.33 (s, 9 H) 2.62 -
2.72 (m, 4
H) 3.58 (s, 2 H) 3.96 - 4.13 (m, 4 H) 6.79 (d, J=8.41 Hz, 1 H) 7.15 - 7.33 (m,
5 H)
By working in an analogous way and by starting from DL-3-[(tert-
butoxycarbonyl)amino]-2-
methylpropanoic acid the following compound was prepared:
ethyl -5-[(tert-butoxycarbonyl)amino]-4-methyl-3-oxopentanoate
1 H NMR (400 MHz, DMSO-D6) b ppm 0.96 (d, 3 H) 1.16 (t, 3 H) 1.34 (s, 9 H)
2.69-2-84 (m, 1
H) 2.85-3.13 (m, 1 H) 3.15-3.2 (m, 1 H) 4.62 (d, 2 H) 4.05 (q, 2H), 6.86 (s, 1
H)
Example 3
Preparation of ethyl Dt_-5-[(tert-butoxycarbonyl)amino]-6-methyl-3-
oxoheptanoate
A solution of 1 g (4.33 mmol) of 3-[(tent butoxycarbonyl)amino]-4-
methylpentanoic acid and
1.04 g (6.4 mmol) of 1,1'-carbonyldiimidazole in 9 mL of THF anhydrous was
left shaking at
room temperature 3 hours. Then, 0.817 g of magnesium chloride, 1.45 g of
potassium ethyl
malonate and 16mL of THF anhydrous were added. The temperature was brought to
48°C
and the suspension left shaking overnight then filtered. THF was removed under
vacuum and
the raw product dissolved in ethyl acetate, and washed three times with an
aqueous solution
of 5% sodium bisulfate, three times with aq. NaHC03 and then with brine, the
organic solution
was dried over sodium sulfate and the solvent removed. The raw product was
purified by flash
chromatography over silica gel thus obtaining 1.06 g of title compound.
1 H NMR (400 MHz, DMSO-D6) ~ ppm 0.8 (d, 6 H) 1.17 (t, 3 H) 1.38 (s, 9 H) 1.57
-1.69 (m, 1
H) 2.45 - 2.65 (m, 2 H) 3.59 (s, 2 H) 3.67 - 3.77 (m, 1 H) 4.10 (q, J=7.07 Hz,
2 H) 6.68 (d,
J=8.78 Hz, 1 H).
27
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
By working in an analogous way and by starting from DL 3-[(tert
butoxycarbonyl)amino]-3-
cyclopropylpropanoic acid the following compound was prepared:
ethyl -5-[(tert-butoxycarbonyl)amino)-5-cyclopropyl-3-oxopentanoate
1 H NMR (400 MHz, DMSO-D6) S ppm 0.08 - 0.42 (m, J=63.53 Hz, 4 H) 0.81 - 0.91
(m, 1 H)
1.20 (t, 3 H) 1.38 (s, 9 H) 2.65 - 2.77 (m, 2 H) 3.59 (s, 2 H) 4.09 (q, 2 H)
6.75 (s, 1 H)
By working in an analogous way and by starting from DL 3-[(tert
butoxycarbonyl)amino]-3-
cyclohexylpropanoic acid the following compound was prepared:
ethyl -5-[(tert-butoxycarbonyl)amino]-5-cyclohexyl-3-oxopentanoate
1 H NMR (400 MHz, DMSO-D6) i5 ppm 0.79 - 1.74 (m, 23 H) 2.44 - 2.79 (m, 2 H)
3.58 (s, 2 H)
3.66 - 3.76 (m, 1 H) 4.08 (q, J=7.19 Hz, 2 H) 6.66 (d, J=9.02 Hz, 1 H).
By working in an analogous way and by starting from 2-benzyl-3-((tert-
butoxycarbonyl)amino]propanoic acid the following compound was prepared:
ethyl 4-benzyl-5-[(tent-butoxycarbonyl)amino]-3-oxopentanoate
ESI (+) MS: mlz 350 (MH+).
Example 4
Preparation of ethyl 2-~2-[(tert-butoxycarbonyi)amino]ethyl}-5-pyridin-4-yl-1H-
pyrrole-3-
carboxylate
540 mg of ethyl 5-[(tert-butoxycarbonyl)amino]-3-oxopentanoate (2.08 mmol) and
208 mg of
sodium hydride (60% dispersion oil, 5.2 mmol) dissolved in 20 mL of THF were
stirred 1 hour
at room temperature and then cooled down to 0°C. A suspension of 735 mg
(3.67 mmol) of 2
bromo-1-pyridin-4-ylethanone in 10 mL of THF was added dropwise and the
mixture was
stirred at 0°C for 4 hours. The resulting solution was dried and then
dissolved in 30 mL of
ethanol; 500 mg (8.47 mmol) of ammonium acetate were added. The solution was
left stirring
5 hours and then dried. The raw product was dissolved in ethyl acetate, washed
three times
with brine and dried over sodium sulfate. The solvent was removed and the raw
product was
purified by flash chromatography over silica gel, thus obtaining 280 mg (0.78
mmol, 37%) of
the title compound.
28
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
1 H NMR (300 MHz, DMSO-D6) b ppm 1.3 (t, J=7.0 Hz, 4 H) 1.3 (s, 9 H) 3.0 (t,
J=7.2 Hz, 2 H)
3.2(m,2H)4.2(q,J=7.OHz,ZH)7.1(d,J=2.6Hz,1H)7.6(d,J=6.4Hz,2H)8.5(d,J=6.2
Hz, 2 H) 11.9 (s, 1 H).
HPLC retention time (RT): 4.9 min; ESI (+) MS: m/z 360 (MH+).
By working in an analogous way and by starting from the appropriate starting
material the
following compounds were prepared:
ethyl 2-d(2S1-2-lltert-butoxvcarbonvllaminot-2-phenvlethvl~-5-pvridin-4-yl-1H-
pyrrole-3-
carboxylate
1 H NMR (400 MHz, DMSO-D6) ~ ppm 1.3 (s, 9 H) 1.3 (t, J=7.1 Hz, 3 H) 3.2 (dd,
J=13.7, 9.0
Hz,2H)4.2(q,J=7.1 Hz,2H)4.9(m,1 H)7.2(m,7H)7.6(d,J=6.2Hz,2H)8.5(d,J=6.2
Hz, 2 H) 11.7 (s, 1 H).
ethyl 2-{(2S)-2-[(tert-butoxycacbonyl)amino]loropyl}-5-pyridin-4-yl-1 H-
pyrrole-3-
carboxylate
1 H NMR (300 MHz, DMSO-D6) b ppm 1.0 (d, J=6.4 Hz, 3 H) 1.3 (s, 9 H) 1.3 (t,
J=7.0 Hz, 3 H)
3.0 (m, 2H) 3.8 (m, 1 H) 4.2 (q, J=7.2, 2 H) 7.1 (d, J=2.9 Hz, 1 H) 7.6 (dd,
J=6.2, 1.8 Hz, 2 H)
8.5 (d, J=6,4, 1.8 Hz, 2 H) 11.7 (s, 1 H).
ethyl 2-1(2Rl-2-f(tert-butoxvcarbonvl)aminol-3-methvlbutyl}-5-pyridin-4-yl-1 H-
pyrrole-3-
carboxylate
1 H NMR (400 MHz, DMSO-D6) i5 ppm 0.92 (d, J=6.71 Hz, 6 H) 1.19 (s, 9 H) 1.28-
1.34 (m, 3
H) 1.67 - 1.78 (m, 1 H) 2.76 - 2.87 (m, 1 H) 3.15 - 3.23 (m, 1 H) 3.63 - 3.74
(m, 1 H) 4.17 -
4.28 (m, 2 H) 6.11 (d, J=9.39 Hz, 1 H) 7.08 (d, J=2.68 Hz, 1 H) 7.60 (dd,
J=4.51, 1.59 Hz, 2 H)
8.51 (dd, J=4.51, 1.46 Hz, 2 H) 11.60 (s, 1 H)
ethyl 2-!2-!(tent-butoxvcarbonvllaminol-3-ohenvlpropvl?-5-pvridin-4-yl-1 H-
pvrrole-3-
carboxylate
1 H NMR (400 MHz, DMSO-D6) b ppm 1.22 (s, 9 H) 1.27 (d, J=7.07 Hz, 3 H) 2.73 -
2.82 (m, 2
H) 2.91 - 2.99 (m, 1 H) 3.13 - 3.22 (m, 1 H) 4.01 - 4.25 (m, 3 H) 6.44 (d,
J=8.90 Hz, 1 H) 7.09
(d, J=2.56 Hz, 1 H) 7.17 - 7.32 (m, 5 H) 7.62 (dd, J=4.63, 1.59 Hz, 2 H) 8.49
(dd, J=4.63, 1.59
Hz, 2 H) 11.71 (s, 1 H)
29
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
ethyl 2-~2~(tert-butoxycarbonyl)amino]-1-rnethylethyl}-5-pyridin-4-yl-1Hp
rrole-3-
carboxylate
1 H NMR (400 MHz, DMSO-D6) i) ppm 1.24 (d, J=7.19 Hz, 3 H) 1.30 (t, J=7.07 Hz,
3 H) 1.35
(s, 9 H) 3.78 - 3.89 (m, 1 H) 4.14 (d, J=7.13, 2 H) 6.89 (s, 1 H) 7.09 (d,
J=2.80 Hz, 1 H) 7.71
(d, J=4.63 Hz, 2 H) 8.51 (d, J=4.51 Hz, 2 H) 11.48 (s, 1 H)
ethyl 2-(2-f(tert-butoxvcarbonvllaminol-2-cvcloaroavlethvl)-5-pyridin-4-yl-1 H-
pyrrole-3-
carboxylate
1 H NMR (400 MHz, DMSO-D6) b ppm -0.08 - 0.37 (m, 4 H) 0.85 - 0.98 (m, 1 H)
1.23 - 1.34
(m, 12 H) 2.99 - 3.38 (m, 3 H) 4.16 - 4.26 (m, 2 H) 6.56 (d, J=8.54 Hz, 1 H)
7.10 (d, J=2.80 Hz,
1 H) 7.64 (dd, J=4.63, 1.59 Hz, 2 H) 8.50 (d, 2 H) 11.73 (s, 1 H)
ethyl 2- 2-[(tert-butoxycarbonyl)amino]-2-cyclohexylethyl}-5-pyridin-4-yl-1H-
pyrrole-3-
carboxylate
1 H NMR (400 MHz, DMSO-D6) i5 ppm 1.20 - 1.22 (m, 23 H) 2.77 - 2.87 (m, 1 H)
3.15 - 3.26
(m, 1 H) 3.57 - 3.75 (m, 1 H) 4.17 - 4.28 (m, 2 H) 6.07 (d, J=9.51 Hz, 1 H)
7.09 (d, J=2.68 Hz,
1 H) 7.61 (dd, J=4.76, 1.59 Hz, 2 H) 8.51 (d, J=5.97 Hz, 2 H) 11.60 (s, 1 H)
ethyl 2-l1-benzyl-2-[(tert-butoxycarbonyl)amino]ethyl}-5-pyridin-4-yl-1H-
pyrrole-3-
carboxylate
HPLC RT 6.42 min; ESI (+) MS: m/z 450 (MH+).
F~cample 5
Preparation of 4-[5-(2-ammonioethyl)-4-(ethoxy-carbonyl)-1H-pyrrol-2-
yl]pyridinium
dichloride
To a solution of 20 mg of ethyl 2-{2-[(tert-butoxycarbonyl)amino]ethyl}-5-
pyridin-4-yl-1 H-
pyrrole-3-carboxylate, 2 mL of HCI 4 M in dioxane were added. The solution was
left shaking 3
hours and then the product was dried under vacuum thus affording the title
compound.
1 H NMR (400 MHz, DMSO-D6) 5 ppm 1.3 (t, J=7.1 Hz, 3 H) 3.2 (m, 4 H) 4.3 (q,
J=7.1 Hz, 2
H) 7.6 (d, J=2.6 Hz, 1 H) 8.1 (m, 3 H) 8.3 (d, J=6.3 Hz, 2 H) 8.7 (d, J=5.7
Hz, 2 H) 13.0 (s, 1
H).
HPLC RT 2.3 min; ESI (+) MS: m/z 260 (MH+).
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
By working in an analogous way and by starting from the appropriate starting
material, the
following compounds were also prepared:
4-[5-[(2S)-2-ammoniopropyl]-4-(ethoxycarbonyl)-1H-pyrrol-2-yl]pyridinium
dichloride
1 H NMR (400 MHz, DMSO-D6) b ppm 1.2 (d, J=6.6 Hz, 3 H) 1.3 (t, J=7.1 Hz, 3 H)
3.5 (m, 3
H) 4.3 (q, J=7.1 Hz, 2 H) 7.6 (d, J=2.7 Hz, 1 H) 8.1 (d, J=3.7 Hz, 3 H) 8.3
(d, J=6.8 Hz, 2 H)
8.7 (d, J=7.0 Hz, 2 H) 13.0 (s, 1 H).
4-[5-[(2S -2-ammonio-2-phen_ylethyl]-4-(ethoxycarbonyl)-1H-pyrrol-2-
yl]pyridinium
dichloride
HP~C RT 2.7 min; ESI (+) MS: m/z 336 (MH+).
ethyl 2-((2S)-2-amino-3-meth r~lbutyl]-5-pyridin-4-yl-1H-pyrrole-3-carboxylate
dihydrochloride
1 H NMR (400 MHz, DMSO-D6) b ppm 0.99 (d, J=7.32 Hz, 6 H) 1.32 (d, J=7.07 Hz,
3 H) 1.86 -
1.98 (m, 1 H) 4.27 (d, J=7.07 Hz, 2 H) 7.65 (d, J=2.44 Hz, 1 H) 8.05 (br.s, 2
H) 8.31 (d, J=6.46
Hz, 2 H) 8.75 (d, J=6.83 Hz, 2 H) 13.11 (s, 1 H)
ethyl 2-(2-amino-3-methvlbutvl)-5-ovridin-4-vl-1H-nvrrole-3-carboxylate
dihydrochloride
ethvl2-(2-amino-3-ohenvlaroavt)-5-pvridin-4-vt-1H-pvrrole-3-carboxylate
dihydrochloride
1 H NMR (400 MHz, DMSO-D6) 8 ppm 1.29 (t, J=7.13 Hz, 3 H) 3.13 - 3.27 (m, 2 H)
3.36 - 3.78
(m, 2 H) 4.16 - 4.25 (m, J=7.13, 1.28 Hz, 2 H) 4.28 - 4.39 (m, 1 H) 7.07 -
7.27 (m, 5 H) 7.52 (d,
J=2.32 Hz, 1 H) 7.98 (br.s., 2 H) 8.39 (d, J=6.71 Hz, 2 H) 8.74 (d, J=6.83 Hz,
2 H) 12.76 (s, 1
H)
ethyl 2-(2-amino-2-cyclohexylethyl)-5-pyridin-4-yl-1 H-pyrrole-3-carboxylate
dihydrochloride
1 H NMR (400 MHz, DMSO-D6) i5 ppm 0.94 - 1.95 {m, 14 H) 4.26 (d, J=7.07 Hz, 2
H) 7.65 (d,
J=2.68 Hz, 1 H) 8.05 (br,s, 2 H) 8.31 (d, J=6.71 Hz, 2 H) 8.74 (d, J=6.95 Hz,
2 H) 13.09 (s, 1
H)
31
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
ethyl 2-{2-amino-1-benzylethyl)-5-pyridin-4-yl-1 H-pyrrole-3-carboxylate
dihydrochloride
1 H NMR (300 MHz, DMSO-D6) S ppm 1.23 (d, J=7.03 Hz, 3 H) 3.20 (s, 3 H) 4.15
(q, J=6.74
Hz, 2 H) 4.26 - 4.39 (m, 1 H) 7.01 - 7.24 (m; 5 H) 7.54 (d, J=2.64 Hz, 1 H)
8.08 (s, 2 H) 8.50
(d, J=6.45 Hz, 2 H) 8.71 (d, J=6.74 Hz, 2 H) 13.12 (s, 1 H)
HPLC RT 3.4 min; ESI (+) MS: mlz 350 (MH+).
ethyl 2-{2-aminopropyl)-5-pyridin-4-yl-1H-pyrrole-3-carboxylate
dihydrochloride
1 H NMR (300 MHz, DMSO-D6) b ppm 1.30 (d, J=7.03 Hz, 3 H) 1.40 (d, J=7.03 Hz,
3 H) 3.20 -
3.50 (m, 2 H) 4.00 - 4.12 (m, 1 H) 4.22 (q, J=7.03 Hz, 2 H) 7.63 (d, J=2.64
Hz, 1 H) 8.12 (s, 2
H) 8.55 (d, J=7.03 Hz, 2 H) 8.72 (d, J=7.03 Hz, 2 H) 13.01 (s, 1 H)
ESI (+) MS: m/z 274 (MH+).
ethyl 2-{2-amino-2-cyclopropylethyl)-5-pyridin-4-yl-1 H-pyrrole-3-carboxylate
dihydrochloride
ESI (+) MS: m/z 300 (MH+).
Example 6
Preparation of 2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-~yrrolo[3,2-c]pyridin-4-
one
hydrochloride
To a solution of 20 mg of 2-[3-(ethoxycarbonyl)-5-pyridin-4-yl-1 H-pyrrol-2-
yl]ethanaminium
chloride in 2 mL of ethanol, about 10 mg of potassium carbonate were added and
the solution
was refluxed for 16 hours. The mixture was cooled to room temperature, the
solvent removed
under evaporation and the raw product was purified by flash chromatography
over silica gel,
thus affording the title compound as a free base.
Sometimes, when required, the free base was dissolved in ethanol, treated with
4 N
hydrochloric acid in dioxane and diluted with ethyl acetate until
precipitation of the
hydrochloride salt that was filtered, thus affording the title compound.
'H NMR (DMSO-ds / 400 MHz) a ppm 2.94 (t, 2H, J=6.83), 3.45 (t, 2H, J=6.83),
7.30 (bs, 1 H),
7.59 (s, 1 H), 8.23 (d, 2H, J=7.08), 8.71 (d, 2H, J=7.08), 12.89 (bs, 1 H)
By working in an analogous way and by starting from the appropriate starting
materials the
following compounds were also obtained.
32
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
10
6S -6-methyl-2-pyridin-4-yl-1,5~6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
1 H NMR (400 MHz, DMSO-D6) i5 ppm 1.3 (d, J=6.5 Hz, 3 H) 2.6 (dd, J=16.1, 10.5
Hz, 1 H)
2.9 (dd, J=16.0, 5.2 Hz, 1 H) 3.8 (m, 1 H) 7.0~ (m, 2 H) 7.6 (d, J=6.2 Hz, 2
H) 8.5 (d, J=6.0 Hz,
2 H) 11.9 (s, 1 H).
(6S}-6-phenyl-2-I~~ridin-4-yl-1,5,6,7-tetrahydro-4H-pyrroloj3,2-c]pyridin-4-
one
1 H NMR (400 MHz, DMSO-D6) b ppm 3.0 (dd, J=16.2, 7.2 Hz, 1 H) 3.3 (dd,
J=16.3, 6.2 Hz, 1
H) 4.9 (dd, J=6.6, 2.4 Hz, 1 H) 7.1 (d, J=2.4 Hz, 1 H) 7.3 (m, 1 H) 7.4 (m, 4
H) 7.4 (d, J=2.3
Hz, 1 H) 7.6 (d, J=6.3 Hz, 2 H) 8.5 (d, J=6.1 Hz, 2 H) 11.9 (s, 1 H).
(6R}-6-isoprop~rl-2-pyridin-4-YI-1,5,6,7-tetrahydro-4H-pyrroloL3,2-c]pyridin-4-
one
hydrochloride
NMR (400 MHz, DMSO-D6) b ppm 0.92 (dd, J=2.19, 6.83 Hz, 6H) i .89 (m, 1 H)
2.86 (m, 2H)
3.53 (m, 1 H) 7.23 (bs, 1 H) 7.58 (d, J=2.31 Hz, 1 H) 8.17 (d, J=7.07 Hz, 2H)
8.70 (d, J=7.07 Hz,
2H) 12.71 (bs, 1 H)
6-benzyl-2-pyridin-4-y!-1,5~6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
1 H NMR (400 MHz, DMSO-D6) 8 ppm 2.58 - 3.12 (m, 4 H) 3.84 - 3.97 (m, 1 H)
6.99 - 7.05 (m,
2 H) 7.23 - 7.39 (m, 5 H) 7.57 (dd, J=6.22, 1.59 Hz, 2 H) 8.47 (dd, J=6.22,
1.46 Hz, 2 H) 11.83
(s, 1 H)
The racemate was subjected to chiral separation so to obtain the pure
enantiomers.
Chiral chromatography was performed on Chiralpack° AD column (2 x 25
cm). Mobile phase
was nHexane/iPropanoI/Methanol 90/10/12.
Analytical conditions: Chiralpack° AD column with precolumn, mobile
phase nHexanel
iPropanoI/Methanol 90/1 OI12.
(6R or 6S)-6-benzyl-2-pyridin-4-yl-1.,5,6,7-tetrahydro-4H=pyrrolo[3,2-
c~pyridin-4-one
RT 12.9 min; enantiameric excess (e.e.) 99%
~6R or 6S)-6-benzyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-c]pyridin-
4-one
RT 17 min; e.e. 99%
33
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
7-methyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
1 H NMR (400 MHz, DMSO-D6) b ppm 1.31 (d, J=6.34 Hz, 3 H) 3.06 - 3.15 (m, 2 H)
3.45 -
3.52 (m, 1 H) 7.01 (d, J=2.44 Hz, 1 H) 7.05 (br.s., 1 H) 7.67 (dd, J=6.34,
1.71 Hz, 2 H) 8.50
(dd, J=6.22, 1.59 Hz, 2 H) 11.72 (s, 1 H)
The racemate was subjected to chiral separation so to obtain the pure
enantiomers. Chiral
chromatography was performed on Chiralpack~ AD column (2 x 25 cm). Mobile
phase was
nHexane/ iPropanol/Methanol 90/10/10.
Analytical conditions: Chiralpack~ AD column with precolumn, mobile phase
nHexane/
iPropanol/Methanol 90/10/10.
~7R or 7S)-7-methyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
RT 10.3 min; e.e. 99%
(7R or 7S)-7-methyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
RT 11.8 min; e.e. 94%
6-isopropyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) b ppm 0.93 (d, J=6.83 Hz, 3 H) 0.94 (d, J=6.95 Hz,
3 H) 1.82 -
1.96 (m, 1 H) 2.80 (dd, J=16.58, 9.51 Hz, 1 H) 2.91 (dd, J=16.71, 5.73 Hz, 1
H) 3.51 - 3.60 (m,
1 H) 7.22 (s, 1 H) 7.57 (d, J=2.44 Hz, 1 H) 8.17 (d, J=7.07 Hz, 2 H) 8.70 (d,
J=7.07 Hz, 2 H)
12.70 (s, 1 H)
The racemate was subjected to chiral separation so to obtain the pure
enantiomers. Chiral
chromatography was performed on Chiracell~ OJ column (5 x 50cm). Mobile phase
was n-
Heptanel Ethanol 75/25.
Analytical conditions: Chiralcell° OJ column with .precolumn, mobile
phase Heptane/ Ethanol
75/25.
The correct absolute configurations were assigned by comparison with (6R)
enantiomer
reported above and obtained by stereospecific synthesis.
34
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
(6R)-6-isopropyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-
one
RT 11.8 min; e.e. 98%
(6S)-6-isopropyl-2-pyridi n-4-yi-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-
one
RT 8.7 min; e.e. 99%
7-6enzyl-2-pyridin-4-yl-1,5,6,7-tetrahy_dro-4H-pyrrolo[3,2-c]pyridin-4-one
1 H NMR (400 MHz, DMSO-D6) 8 ppm 2.67 - 2.77 (m, 2 H)3.05-3.12 (m, 1 H) 6.99 -
7.02 (br.s,
1 H) 7.04 (d, J=2.44 Hz, 1 H) 7.23 - 7.40 (m, 5 H) 7.67 (dd, J=6.22, 1.59 Hz,
2 H) 8.52 (d,
J=6.10 Hz, 2 H) 11.87 (s, 1 H)
6-cyclopropyl-2-pyridin-4-yl-1,5,6,7-tefrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
1 H NMR (400 MHz, DMSO-D6) 8 ppm 0.26 - 0.52 (m, 4 H) 0.94 -1.09 (m, 1 H) 2.78
- 3.08 (m,
3 H) 7.03 (d, J=2.44 Hz, 1 H) 7.07 (d, J=1.10 Hz, 1 H) 7.62 (d, J=6.22 Hz, 2
H) 8.50 (d, J=6.22
Hz, 2 H) 11.92 (s, 1 H)
The racemate was subjected to chiral separation so to obtain the pure
enantiomers. Chiral
chromatography was performed on Chiracell° OJ column (5 x 50cm). Mobile
phase was n-
Heptane/ Ethanol/Methanol 75/20/5.
Analytical conditions: Chiralcell° OJ column, mobile phase was n-
Heptane/ EthanoI/Methanol
75/20/5.
(6R or 6S)-6-cyclopropyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-
c]pyridin-4.-one
RT 6.3 min; e.e. 99%
(6R or 6S)-6-cycloprop_yl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-
c]pyridln-4-one
RT 8.6 min; e.e. 96%
6-cyclohexyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
1 H NMR (400 MHz, DMSO-D6) 5 ppm 0.98 - 1.80 (m, 11 H) 2.70 - 2.89 (m, 2 H)
3.44 - 3.54
(m, 1 H) 6.93 (s, 1 H) 6.99 (d, 1 H) 7.60 (dd, J=6.22, 1.59 Hz, 2 H) 8.48 (dd,
J=6.10, 1.46 Hz,
2 H) 11.87 (s, 1 H)
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
Example T
Preparation of 6,6-dlmethyt-2,4-dioxopiperidine
A solution of ethyl 3-methylbut-2-enoate (1 g, 7.8 mmol) in anhydrous ethanol
(12 mL) was
cooled to -20 °C and saturated with gaseous ammonia. The tube was
sealed and kept at
90°C for 24 hours. The reaction was cooled to room temperature, bubbled
with nitrogen to
eliminate the residual ammonia and treated with a 4 N solution of HCI in
dioxane (1.9 mL).
After 30 minute stirring, the mixture was evaporated under reduced pressure to
give ethyl 3-
amino-3-methylbutanoate hydrochloride as a grey solid (1.19 g, Y=84%).
'H NMR (CDCI3 / 400 MHz) b ppm 1.2 (t, 3H), 1.26 (s, 6H), 2.65 (s, 2H), 4.1
(q, 2H), 8.27 (bs,
3H).
Ethyl 3-amino-3-methylbutanoate hydrochloride (0.87 g, 4.79 mmol) was
suspended on
methylene chloride (12 mL) and triethylamine (1.4 mL, 2.1 eq.). The mixture
was cooled to
0°C and treated dropwise with ethyl 3-chloro-3-oxopropanoate (0.64 mL,
1.05 eq.). The
reaction was kept at room temperature for 2 hours, diluted with methylene
chloride, washed
with 1 N HCI and then with 5% NaHC03, dried over Na2S04 and evaporated to
dryness to
obtain ethyl 3-[(3-ethoxy-3-oxopropanoyl)amino]-3-methylbutanoate (1.2g,
Y=97%) as a red
oil.
zo
'H NMR (DMSO-ds / 300 MHz) S ppm 1.11-1.21 (m, 6H), 1.29. (s, 6H), 2.71 (s,
2H), 3.14 (s,
2H), 3.95-4.15 (m, 4H), 7.75 (bs, 1H).
To a solution of sodium ethoxide, obtained from sodium metal (0.122 g, 5.55
mmol) in
anhydrous ethanol (7 mL), a solution of ethyl 3-[(3-ethoxy-3-
oxopropanoyl)amino]-3-
methylbutanoate (1.2 g, 4.62 mmol) in dry toluene (7 mL) was added dropwise at
room
temperature, under stirring. The reaction mixture was heated at 80°C
for 2 hours then it was
concentrated to reduced volume and the residue was dissolved in toluene (15
mL). The
organic phase was extracted with water (40 mL), the aqueous phase was
acidified to pH 2-3
with 1 N HCI and extracted with ethyl acetate (4 x 50 mL). The organic phase
was washed
with brine, dried over anhydrous sodium sulphate and concentrated to give
ethyl 6,6-dimethyl-
2,4-dioxopiperidine-3-carboxylate as a yellow solid (0.7 g, Y=71 %) which was
used for the
next step without further purification.
36
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
Ethyl 6,6-dimethyl-2,4-dioxopiperidine-3-carboxylate (0.69 g, 3.23 mmol) was
dissolved in
acetonitrile containing 1 % of water (15 mL) and the resulting solution was
refluxed for 2 hours.
After evaporating to dryness, the crude material was suspended in isopropyl
ether, kept under
vigorous stirring and filtered to give the title compound (387 mg, Y=85%) as a
light brown
solid.
'H NMR (DMSO-ds / 300 MHz) b ppm 1.18 (s, 6H), 2.49 (bs, 2H), 3.13 (bs, 2H),
8.13 (bs, 1 H).
Example 8
Preparation of 5-phenylpiperidine-2,4-dione
Ethyl cyano(phenyl)acetate (14.9 g, 78.83 mmol) was dissolved in absolute
ethanol (400 mL)
containing 37% hydrochloric acid (40 mL). The solution was treated with 10% Pd-
C (2 g) and
kept under hydrogen (40 psi) in a Parr apparatus for 24 hours. The resulting
mixture was
filtered to remove the catalyst and evaporated to dryness under reduced
pressure. The
residue was taken up with ethyl acetate, kept under vigorous stirring for 15
minutes and
filtered. Obtained ethyl 3-amino-2-phenylpropanoate hydrochloride (11 g,
Y=60%).
'H NMR (DMSO-de / 300 MHz) 8 ppm 1.11 (t, 3H), 3.05 (dd, 1 H, J=12.9, 6.15),
3.42 (dd, 1 H,
J=12.9, 8.79), 4.07 (m, 3H), 7.35 (m, 5H), 8.15 (br, 3H)
Ethyl 3-amino-2-phenylpropanoate hydrochloride (4.38 g, 19.13 mmol) was
suspended in
methylene chloride (80 mL) and triethylamine (5.86 mL, 2.2 eq.). The mixture
was cooled to
0°C and treated dropwise with ethyl 3-chloro-3-oxopropanoate (2.69 mL,
1.1 eq.). The
reaction was kept at room temperature for one hour, diluted with methylene
chloride, washed
25' with 1 N HCI and then with 5% NaHC03, dried over Na2S04 and evaporated to
dryness. The
crude material was chromatographed on silica gel, eluting with hexane/ethyl
acetate 1/1, to
give 3-(2-ethoxycarbonyl-acetylamino)-2-phenyl-propionic acid ethyl ester
(4.24 g, Y=72%) as
an oil.
'H NMR (CDCI3 / 300 MHz) i5 ppm 1.21 (t, 3H), 1.27 (t, 3H), 3.26 (s, 2H), 3.73
(m, 2H), 3.89
(dd, 1H, J=6.16, 8.50), 4.17 (m, 4H), 7.29 (m, 6H).
Sodium (380 mg, 16.52 mmol) was dissolved in anhydrous ethanol (13 mL) and the
resulting
solution was treated dropwise with 3-(2-ethoxycarbonyl-acetylamino)-2-phenyl-
propionic acid
37
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
ethyl ester (4.23 g, 13.76 mmol) dissolved in anhydrous toluene (35 rnL). The
reaction was
kept at 80°C for 1.5 hours. After cooling, the mixture was extracted
with water. The aqueous
extracts were acidified with 2 N HCI, extracted with ethyl acetate and the
organic layers were
collected, dried over Na2S04 and evaporated to dryness to obtain ethyl 2,4-
dioxo-5-
phenylpiperidine-3-carboxylate (1.73 g, Y=48%) which was used for the next
step without
further purification.
Ethyl 2,4-dioxo-5-phenylpiperidine-3-carboxylate (1.73 g, 6.63 mmol) was
dissolved in
acetonitrile containing 1 % of water (30 mL) and the resulting solution was
refluxed for 2 hours.
After evaporating to dryness, the crude material was chromatographed on silica
gel, eluting
with methylene chloride/methanol 92/8, to give the title compound (780 mg,
Y=62%) as a
solid.
'H NMR (DMSO-dfi / 300 MHz) i5 ppm 3.25 (d, 1 H, J=18.75) 3.42-3.70 (m,2H),
3.61 (d, 1 H,
J=18.75), 3.81 (dd, 1 H, J=5.57, 9.67), 7.26 (m, 5H), 8.20 (bs, 1 H),
Example 9
Preparation of ethyl 2-(aminomethyl)-3-methylbutanoate hydrochloride
Ethyl 2-cyano-3-methylbut-2-enoate (5.0 g, 32.6 mmol) was dissolved in 320 mL
of absolute
EtOH. 700 mg of Pt02 and 12 mL of 4M HCI were added. The reaction mixture was
hydrogenated at room temperature for 5 hours (30 psi). Filtration on a celite
pad and
evaporation of the solvent afforded crude title compound (quantitative yield).
1 H NMR (400 MHz, DMSO-D6) 5 ppm 0.90 (d, J=6.83 Hz; 3 H.) 0.93 (d, J=6.83 Hz,
3 H) 1.24
(t, J=7.13 Hz, 3 H) 1.92 - 2.06 (m, 1 H) 2.53 - 2.60 (m, 1 H) 2.84 - 3.17 (m,
2 H) 4.05 - 4.24 (m,
2H)7.84(s,3H)
ESI (+) MS: m/z 160 (MH+).
By working in an analogous way and by starting from the suitable cyano
derivative, the
following compounds were also prepared:
ethyl 2-(aminomethyl)-3-methylpentanoate hydrochloride
'H NMR (DMSO-dfi / 400 MHz) b ppm 0.80 (m, 6 H) 1.23-1.40 (2 m, 5 H) 1.76 (m,
1 H) 2.69
(m, 1 H} 2.89 (m, 1 H), 3.09 (m, 1 H) 4.14 (m, 2H) 7.82 (s, 3H)
38
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
ESI (+) MS: mlz 174 (MH+).
ethyl 1-(aminomethyl)cyclopropanecarboxylate hydrochloride
ESI (+) MS: m/z 144 (MH+).
Example 10
Preparation of ethyl 2-~[(3-ethoxy-3-oxopropanoyl)amino]methyl}-3-
methylbutanoate
Crude ethyl 2-(aminomethyl)-3-methylbutanoate hydrochloride was dissolved in
200 mL of dry
DCM and DIPEA was added (14 mL, 2.5 eq). After cooling to 0°C, ethyl 3-
chloro-3-
oxopropanoate was added (6.3 mL, 35.4 mmol). After stirring at room
temperature overnight,
the reaction mixture was diluted with DCM and washed with aq. KHS04 5% (x2),
aq. NaHC03
sat. sol. (x2) and brine. The organic layer was dried over Na2S04, filtered
and evaporated to
dryness. Column chromatography (hexane/EtOAc=7/3 -> 1/1 ) afforded 8.35 g
(30.55 mmol,
93.4% yield) of target product.
1H NMR (400 MHz, DMSO-D6) S ppm 0.89 (d, J=6.82 Hz, 3 H) 0.93 (d, J=6.83 Hz, 3
H) 1.20
(m, 6 H) 1.82 -1.90 (m, 1 H) 2.35 (m, 1 H) 3.19 - 3.33 (2 m, 4 H) 4.06 (m, 4
H) 8.11 (t, J=5.12
Hz, 1 H)
ESI (+) MS: m/z 274 (MH+).
By working in an analogous way and by starting from the suitable hydrochloride
derivative, the
following compounds were prepared:
ethyl 2-f [(3-ethoxy-3-oxopropanovl)amino]methyl;r-3-methylpentanoate
'H NMR (DMSO-ds / 400 MHz) S ppm 0.90 (m, 6 H) 1.19-1.65 (3 m, 9 H) 2.47 (m, 1
H) 3.20
(m, 4H), 4.08 (m, 4H), 8.09 (m, 1 H)
ESI (+) MS: m/z 288 (MH+),
ethyl 1-{[(3-ethoxy-3-oxopropanoyl)amino]methylycyclopropanecarboxylate
ESI (+) MS: m/z 258 (MH+).
39
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
Example 11
Preparation of 5-isopropylpiperidine-2,4-dione
Crude ethyl 2-{[(3-ethoxy-3-oxopropanoyl)amino]methyl}-3-methylbutanoate (8.35
g, 30.55
mmol) was dissolved in 215 mL of dry toluene and heated to 100°C. 6.9
mL of sodium
methoxide 30 wt.% solution in methanol were added (36 mmol) and the reaction
mixture was
refluxed for 4 hours. After cooling at room temperature, the organic phase was
washed with
water (x2). The aqueous layers were collected, acidified (10% HCI) and
extracted with DCM
(x4). The organic layers were collected and evaporated to dryness. The crude
was treated
with 250 mL of 10% AcOH in water and refluxed for 3 hours. The reaction
mixture was
neutralized with NaHC03 (--pH 7) and extracted with DCM (x5). The organic
layers were
collected, dried (Na2S04), filtered and evaporated to dryness. Column
chromatography
(DCM/EtOH=9713) afforded 2.35 g of target product (15.14 mmol, 49.6% yield).
1 H NMR (400 MHz, DMSO-D6) i5 ppm 0.85 (d, J=6.83 Hz, 3 H) 0.94 (d, J=6.95 Hz,
3 H) 2.07 -
2.17 (m, 1 H) 2.25 - 2.33 (m, 1 H) 3.09 - 3,41 (m, 4 H) 8.03 (s, 1 H)
ESI (+) MS: m/z 156 (MH+).
By working in an analogous way and by starting from the suitable aminoester
derivative, the
following compounds were prepared:
5-sec-butylpiperidine-2,4-dione
'H NMR (DMSO-de I 400 MHz) 5 ppm 0.87 (m, 6 H) 1.36 (m, 2 H) 1.95 (m, 1 H)
2.35 (m, 1 H)
3.34 (m, 4H), 8.02 (s, 1 H)
ESI (+) MS: m/z 170 (MH+).
5-azaspiro(2.5]octane-6,8-dione
1 H NMR (400 MHz, DMSO-D6) i5 ppm 0.95 - 1.02 (m, 2 H) 1.09 - 1.15 (m, 2 H)
3.33 (s, 2 H)
3.42 (s, 2 H) 8.22 (s, 1 H)
ESI (+) MS: m/z 140 (MH+).
5,5-diethylpiperidine-2,4-dione
1 H NMR (400 MHz, DMSO-D6) b ppm 0.77 (t, J=7.56 Hz, 6 H) 1.46 (q, J=7.68 Hz,
4 H) 3.23
(d, J=3.78 Hz, 2 H) 3.26 (s, 2 H) 7.98 (s, 1 H)
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
Example 12
6-Benzylpiperidlne-2,4-dione
A mixture of beta-homophenylalanine (9.1 g, 50.94 mmol), di-tert-butyl
dicarbonate (12.2 g,
56.1 mmol), dioxane (180 mL), water (18 mL) and triethylamine (8.5 mL) was
stirred at RT
overnight. After concentration and multiple strippings with toluene, 3-[(tert-
butoxycarbonyl)amino]-4-phenylbutanoic acid was obtained as an oil and used
directly in the
next step. It was dissolved in dry dichloromethane (370 mL), Meldrum acid (8.1
g, 56_1 mmol)
and DMAP (9.7 g, 79 mmol) were added to it, the mixture was cooled to -
5°C and
dicyclohexylcarbodiimide (12.6 g, 61 mmol) was added. After addition the
reaction mixture
was kept in refrigerator overnight. The precipitate was filtered off and
washed with
dichloromethane. The filtrate was diluted with ethylacetate, washed in
sequence with 10% aq
KHS04, water, brine then concentrated to yield crude tent-butyl 1-benzyl-3-
(2,2-dimethyl-4,6-
dioxo-1,3-dioxan-5-yl)-3-oxopropylcarbamate that was dissolved in ethylacetate
(250 mL) and
refluxed 2 h. After concentration and treatment with diisopropylether the
crystallized
compound was filtered and washed to give tert-butyl 2-benzyl-4,6-
dioxopiperidine-1-
carboxylate as a white powder in 75% overall yield.
The t-butoxycarbonyi group could be removed by acidic treatment (4M HCI in
dioxane) at RT.
1 H NMR (400 MHz, DMSO-D6) b ppm 2.32 (dd, J=15.73, 8.17 Hz, 1 H) 2.42 (dd,
J=16.34,
4.76 Hz, 1 H) 2.66 - 2.74 (m, 1 H) 2.87 - 3.02 (m, 2 H) 3.25 - 3.40 (m, 1 H)
3.84 - 3.93 (m, 1 H)
7.20 - 7.36 (m, 5 H) 8.14 (s, 1 H).
By working in an analogous way the following compounds were also obtained:
6-isopropylpiperidine-2,4-dione
ESI (*) MS: m/z 156 (MH+).
6-methylpiperidine-2,4-dione
ESI (+) MS: m/z 128 (MH+).
41
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
5,5-dimethylpiperidine-2,4-dione
1 H NMR (300 MHz, DMSO-D6) b ppm 1.0 (s, 6 H) 3.15 (s, 2 H) 3.25 (s, 2 H) 8.0
(s, 1 H).
6-(2-phenylethyl)piperidine-2,4-dione
ESI (+) MS: m/z 218 (MH+).
Example 13
Preparation of 5-benzylpiperidine-2,4-dione
To a solution of tert-butyl 2,4-dioxopiperidine-1-carboxylate (324 mg, 1.5
mmol) in dry THF (10
mL), cooled to -20°C under nitrogen, lithium bis(trimethylsilyl)amide
(LiHMDS) (4 mL of 1 M
solution in THF) was added dropwise. After 20 min stirring, 3.0 eq of benzyl
bromide were
added and the solution was stirred at -20°C for 2 hours. The reaction
mixture was poured into
5% aq KHS04 and extracted with DCM (x2). To the collected (200 mL) organic
layers, 20 mL
of TFA were added and the resulting solution was stirred at room temperature
for 2 hours.
After evaporation, the residue was purled by column chromatography
(hexane/EtOAc 1:2)
affording 150 mg of target product (0.74 mmol, 49%).
1 H NMR (400 MHz, DMSO-D6) b ppm 2.81 (m, 1 H), 3.12 (m, 2 H) 3.34 (m, 4 H),
7.23 - 7.30
(m, 5H), 7.99 (s, 1 H)
ESI (+) MS: m/z 204 (MH+).
By working in an analogous way and by using the suitable alkyl halide, the
following
compounds were prepared:
5-isobutyipiperidine-2,4-dione
1 H NMR (400 MHz, DMSO-D6) a ppm 0.88 (m, 6H), 1.16 (m, 1 H), 1.53 (m, 1 H),
1.61 (m, 1 H),
3.08 (m, 1 H) 3.20 - 3.40 (m, 4 H), 8.03 (s, 1 H)
ESI (+) MS: m/z 170 (MH+).
5-ethylpiperidine-2,4-dione
1 H NMR (400 MHz, DMSO-D6) 8 ppm 0.89 (t, J=7.56, 3H), 1.35 (m, 1 H), 1.69 (m,
1 H), 2.39
(m, 1 H), 3.14 - 3.38 (m, 4 H), 8.05 (s, 1 H)
ESI (+) MS: m/z 142 (MH+).
42
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
Example 14
Preparation of tert-butyl 5-ethyl-2,4-dioxopiperidine-1-carboxylate
To a solution of tert-butyl 2,4-dioxopiperidine-1-carboxylate (1.92 g, 9.0
mmol), in dry THF (65
mL) and cooled to -20°C under nitrogen, lithium
bis(trimethylsilyl)amide (LiHMDS) (27 mL of 1
M solution in THF) was added dropwise. After 20 min stirring, 2.53 mL (4.9 g,
31.3 mmol) of
iodoethane were added and the solution was stirred at -20°C for 2
hours. The reaction
mixture was poured in 5% aq KHS04 and extracted with DCM (x2). The collected
organic
layers were washed with water, dried over Na2S04 and evaporated to dryness.
The residue
was purified by column chromatography (n-HexanelEtOAc 1:1 ) affording 1.4 g of
target
product (5.8 mmol, 64%).
ESI (+) MS: m/z 242 (MH+).
By working in an analogous way and by using 1-iodo-3-methylbutane, the
following compound
was prepared:
tent-butyl 5-isobutyl-2,4-dioxopiperidine-1-carboxylate
ESI (+) MS: m/z 270 (MH+).
Example 15
Preparation of 2-bromo-1-pyridin-4-ylethanone hydrobromide
To a stirred solution of 4-acetylpyridine (10 mL, 90 mmols) in glacial acetic
acid (40 mL) and
48% hydrobromic acid (15 mL), bromine (4.65 mL, 90 mmols) in glacial acetic
acid (10 mL)
was added dropwise. After addition, the solution was stirred at room
temperature overnight.
The white precipitate was filtered off and washed with absolute ethanol, thus
obtaining the title
compound (22.2 g Y=90%) as a white solid containing traces of
dibromoderivative, that was
used as such in the next step.
'H NMR (DMSO-ds / 300 MHz) i5 ppm 5.05 (s, 2 H) 8.15 (d, 2 H) 9.0 (d, 2 H).
By working in an analogous way and by starting from 4-propionylpyridine, the
following
compound was prepared:
43
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
2-bromo-1-pyridin-4-ylpropan-1-one hydrobromide
H NMR (DMSO-ds / 400 MHz) b ppm 1.75 (d, 3 H) 5.85 (q, 1 H) 8.1 (d, 2 H) 8.95
(d, 2 H).
Example 16
Preparation of 2-bromo-1-(3-fluoropyridin-4-yl)ethanone hydrobromide
Into a stirred solution of 3-fluoropyridine (14 g, 144.2 mmol) in anhydrous
THF (150 mL),
cooled to -78°C and under argon, 79.2 mL (158.6 mmol) of a 2N solution
of
lithiumdiisopropylamide (LDA) in n-heptane, THF, ethylbenzene, were slowly
dropped in about
1 h. After stirring for 2.5h a cooled solution (ca. 0°C)of acetaldehyde
(8.9 mL, 158.5 mmol) in
25 mL of anhydrous THF was slowly dropped and the reaction mixture was stirred
at -78°C
for 1.5 h. The solution was warmed to -30°C and a solution of ammonium
chloride (150g) in
700 mL of water was added. The mixture was extracted with ethylacetate (3 x
400 mL) and
the organic layers were washed with brine (4 x 200 mL) and dried over sodium
sulfate. After
concentration the oil was crystallized with n-hexane (40 mL) and 15.6 g (76%
yield) of 1-(3-
fluoropyridin-4-yl)ethanol were obtained.
A mixture of 1-(3-fluoropyridin-4-yl)ethanol (10 g, 70.3 mmol) and commercial
activated Mn02
(8 g, 92.1 mmol) in toluene (100 mL) were refluxed until disappearance of
starting material.
After cooling the mixture was filtered on a bed of celite, the cake washed
with toluene and the
organic phases concentrated to give 3-fluoro-4-acetyl pyridine (6.9 g, 70%)
that was used
directly in the next step.
To a stirred solution of 3-fluoro-4-acetylpyridine (5.3 g, 38.1 mmol) in
glacial acetic acid (14
mL) and 48% hydrobromic acid (5.3 mL), bromine (2 mL, 38 mmol) in glacial
acetic acid (5.3
mL) was added slowly and dropwise. After addition, the solution was stirred at
60°C for 2.5 h
then it was cooled down and ethylacetate (70 mL) was added. After 30' stirring
the mixture
was filtered and the solid was washed thoroughly with ethylacetate and dried.
The title
compound was obtaind in 82% yield (9.4 g).
'H NMR (DMSO-ds / 300 MHz) i5 ppm 4.88 (s, 2 H) 7.83 (dd, 1 H) 8.62 (dd, 1 H)
8.81 (d, 1 H).
44
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
Example 17
Preparation of (7S,7R)-7-phenyl-2-p~idin-4-yl-1,5,6,7-tetrahydro-4H-
pyrrolo[3,2-
clpyridin-4-one hydrochloride
A solution of 5-phenylpiperidine-2,4-dione (556 mg, 2.94 mmol) and ammonium
acetate (603
mg, 7.83 mmol) in ethanol (20 mL) was treated with 2-bromo-1-pyridin-4-
ylethanone
hydrobromide (550 mg, 1.96 mmol) at room temperature for one hour. The mixture
was
concentrated under reduced pressure, diluted with ethyl acetate and washed
with 5%
NaHC03 solution and with water. The organic layer was dried over Na2S04 and
evaporated to
dryness. The crude material was chromatographed on silica gel eluted with
methylene
chloride/methanol 9/1 to give the desired compound as a red foamy free base
solid. The free
base was dissolved in ethanol, treated with 4 N hydrochloric acid in dioxane
and diluted with
ethyl acetate until precipitation of the hydrochloride salt that was filtered,
thus affording the title
compound (220 mg; Y=34%).
'H NMR (DMSO-dg / 400 MHz) i5 ppm 3.87 (dd, 2H, J=5.73, 11.95), 4.41 (t, 1 H),
7.18-7.38 (m,
6H), 7.66 (s, 1 H), 8.18 (d, 2H, J=7.08), 8.70 (d, 2H, J=7.08), 12.55 (bs, 1
H).
The title compound as a racemic (7S,7R) mixture was separated through chiral
column
chromatography according to conventional methods, for instance by using a
CHIRALPACK°
AD column (2 x 25 cm) and by eluting with a mixture n-hexane:EtOH =85:15, so
as to afford
the desired compounds as (7R) and (7S) enantiomers, which absolute
stereochemistry was
however not determined:
Analytical conditions: Chiralpack~ AD column with precolumn, mobile phase n-
Hexane:EtOH
=85:15
(7R or 7S)-7-phenyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-clpyridin-
4-one
hydrochloride;
RT 20 min; e.e. 98%
(7R or 7S)-7-phenyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
hydrochloride.
RT 27 min; e.e. 96%
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
Example 18
Preparation of 6,B-dimethyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolof3,2-
c]pyridin-4-
one hydrochloride
A suspension of 6,6-dimethylpiperidine-2,4-dione (225 mg, 1.6 mmoi) and 2-
bromo-1-pyridin
4-ylethanone hydrobromide (300 mg, 1.06 mmol) in ethanol (12 mL) was treated
with
ammonium acetate (329 mg, 4.27 mmol) and kept at room temperature overnight.
The mixture
was evaporated under reduced pressure, taken up with water (14 mL) and
filtered to give 200
mg of the title compound, as a pink solid free base. The free base was
dissolved in methanol
(14 mL), treated with 4 N hydrochloric acid in dioxane (0.5 mL) and diluted
with ethyl acetate
until precipitation of the hydrochloride salt that was filtered, thus
affording the title compound
(192 mg, Y=64%) as a white solid.
'H NMR (DMSO-ds / 400 MHz) ~ ppm 1.29(s, 6H), 2.90 (s, 2H), 7.27 (s, 1H), 7.59
(s, 1H),
8.18 (d, 2H, J=7.07), 8.70 (d, 2H, J=7.07), 12.65 (bs, 1 H).
ZS
Example 19
Preparation of 7-isopropyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-p rLrroio(3,2-
c]pyridin-4-
one
A suspension of 5-isopropylpiperidine-2,4-dione (1.9 g, 12.24 mmol) and 2-
bromo-1-pyridin-4
2o ylethanone hydrobromide (2.6 g, 9.42 mmol) in ethanol (120 mL) was treated
with ammonium
acetate (2.9 g, 37.7 mmol) at room temperature The resulting solution was
stirred overnight.
The mixture was concentrated under reduced pressure, diluted with ethyl
acetate and washed
with NaOH 0.5 M (pH=9). The aqueous layer was extracted with ethyl acetate
(x5). The
collected organic layers were dried over Na2S04 and evaporated to dryness. The
crude
25 material was chromatographed on silica gel, eluting with methylene
chloride/ethanol 10/1, to
give the desired compound (1.4 g, 5.48 mmol, 58.2 %).
1 H NMR (400 MHz, DMSO-D6) i5 ppm 0.92 (d, J=6.95 Hz, 3 H) 0.94 (d, J=6.70 Hz,
3 H) 1.95 -
2.13 (m, 1 H) 2.69 (m, 1 H) 3.35 (m, 1 H) 3.50 (m, 1 H) 6.97 (d, J=3.61 Hz, 1
H) 7.00 (d,
30 J=2.43 Hz, 1 H) 7.65 (d, J=6.22 Hz, 2 H) 8.50 (d, J=6.22 Hz, 2 H) 11.74 (s,
1 H)
ESI (+) MS: m/z 256 (MH+).
The title compound as a racemic (75,7R) mixture was separated by chiral column
chromatography according to conventional methods, for instance by using a
CHIRALPACK~
46
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
AD column and by eluting with a mixture n-heptane:ethanol=78:22, so as to
afford the desired
compounds as (7R) and (7S) enantiomers, which absolute stereochemistry was
however not
determined.
The free base was dissolved in ethanol, treated with 4 N hydrochloric acid in
dioxane and
diluted with ethyl acetate until precipitation of the hydrochloride salt that
was filtered, thus
affording the two hydrochloride enantiomers.
By working in an analogous way and by starting from the suitable piperidine-
dione derivative,
the following compounds were prepared:
7-sec-butyl-2-pyridin-4-yl-1 5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
' H NMR (DMSO-d fi / 400 MHz) b ppm 0.87 (m, 6 H) 1.17 -1.50 (m, 2 H) 1.89 (m,
1 H) 2.86 (m,
1 H) 3.29 - 3.54 (m, 2H), 6.97 (s, 1 H), 7.02 (s, 1 H), 7.68 (m, 2H), 8.51 (m,
2H), 11.72 {s, 1 H)
ESI (+) MS: mlz 270 (MH+).
2'-pyridin-4-yl-5',6'-dihydrospiro[cyclopropane-1,7'-pyrrolo[3,2-c]pyridin]-
4'(1'H -one
1 H NMR (400 MHz, DMSO-D6) i5 ppm 0.96 - 1.04 (m, 2 H) 1.22 - 1.31 (m, 2 H)
3.27 (d,
J=2.44 Hz, 2 H) 7.03 (d, J=2.44 Hz, 1 H) 7.12 (t, J=2.50 Hz, 1 H) 7.65 (d,
J=6.22 Hz, 2 H) 8.49
(d, J=6.22 Hz, 2 H) 11.15 (s, 1 H)
ESI (+) MS: m/z 240 (MH+).
7-isobutyl-2-pyrid i n-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
1 H NMR (400 MHz, DMSO-D6) i5 ppm 0.93 (d, J=6.46 Hz, 3 H), 0.97 (d, J=6.47
Hz, 3 H), 1.45
- 1.70 (m, 3H), 2.99 (m, 1 H), 3.17 (m, 1 H), 3.50 (m, 1 H), 7.00 (s, 1 H),
7.02 (s, 1 H), 7.60 (m,
2H), 8.50 (m, 2H) 11.69 (s, 1 H).
ESI (+) MS: m/z 270 (MH+).
7-ethyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
1 H NMR (400 MHz, DMSO-D6) i5 ppm 0.96 (t, J=7.44 Hz, 3 H), 1.59 (m, 1 H),
1.82 (m, 1 H),
2.86 (m, 1 H), 3.21 (m, 1 H), 3.53 (m, 1 H), 7.00 (s, 1 H), 7.01 (s, 1 H),
7.65 (m, 2H), 8.49 (m, 2H),
11.75 (s, 1 H)
ESI (+) MS: m/z 242 (MH+).
47
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
The racemate was subjected to chiral separation so to obtain the pure
enantiomers. Chiral
chromatography was performed on CHIRALPACI(° AS (5 x 50 cm). Mobile
phase was -n-
Hex/EtOHIMeOH 70:23:7
Analytical conditions: Chiralpack~ AS column, mobile phase n-Hex/EtOHIMeOH
70:10:20
(7R or 7S)-7-ethyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
RT 5.7 min; e.e. 99.5%
(7R or 7S)-7-ethyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
RT 9.3 min; e.e. 97%
6-isopropyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) 8 ppm 0.93 (d, J=6.83 Hz, 3 H) 0.94 (d, J=6.95 Hz,
3 H) 1.82
1.96 (m, 1 H) 2.80 (dd, J=16.58, 9.51 Hz, 1 H) 2.91 (dd, J=16.71, 5.73 Hz, 1
H) 3.51 - 3.60 (m,
1 H) 7.22 (s, 1 H) 7.57 (d, J=2.44 Hz, 1 H) 8.17 (d, J=7.07 Hz, 2 H) 8.70 (d,
J=7.07 Hz, 2 H)
12.70 (s, 1 H)
The racemate was subjected to chiral separation so to obtain the pure
enantiomers. Chiral
chromatography was performed on CHIRALCELL° OJ (5 x 50 cm). Mobile
phase was n-
HexIEtOH 75:25. Correct absolute configurations were assigned by comparison
with (6R)
enantiomer reported in Example 6 and obtained by stereospecific synthesis.
~s-isopropyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) b ppm 0.93 (dd, J=2.32, 6.95 Hz, 6H) 1.70 (m, 1 H)
2.86 (m,
2H) 3.63 (m, 1 H) 7.22 (bs, 1 H) 7.56 (d, J=2.32 Hz, 1 H) 8.17 (d, J=7.08 Hz,
2H) 8.70 (d, J=7.08
Hz, 2H) 12.70 (bs, 1 H)
48
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
(6R)-6-isopropyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-
one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) i5 ppm 0.92 (dd, J=2.19, 6.83 Hz, 6H) 1.89 (m, 1 H)
2.86 (m,
2H) 3.53 (m, 1 H) 7.23 (bs, 1 H) 7.58 (d, J=2.31 Hz, 1 H) 8.17 (d, J=7.07 Hz,
2H) 8.70 (d, J=7.07
Hz, 2H) 12.71 (bs, 1 H).
6-isobutyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) 8 ppm 0.91 (dd, J=6.58, 10.85 Hz, 6H) 1.38 (m, 1 H)
1.53 (m,
1 H) 1.76 (m, 1 H) 2.70 (dd, J= 8.42, 16.34 Hz, 1 H) 3.05 (dd, J=5.36, 16.34,
1 H) 3.74 (m, 1 H)
7.27 (bs, 1H) 7.58 (d, J=2.32 Hz, 1H) 8.18 (d, J=7.07 Hz, 2H) 8.71 (d, J=7.07
Hz, 2H) 12,72
(bs, 1 H)
The racemate (as N-Boc derivative) was subjected to chiral separation so to
obtain the pure
enantiomers. Chiral chromatography was performed on CHIRALPACK~' AD (5 x 50
cm).
Mobile phase was EtOH/iPrOH/n-Heptane 60:30:10.
Analytical conditions: Chiralpack~ AD column with precolumn, mobile phase
EtOH/iPrOH/n-
Heptane 60:30:10.
(6R or 6S)-6-isobutyl-2-p,~ridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-
c]pyridin-4-one
RT 6.3 min; e.e. 99%
{6R or 6S)-6-isobutyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-
c]pyridin-4-one
RT 11.3 min; e.e. 98%
7,7-d imethyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-clpyrldin-4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) ~ ppm 1.38 (s, 6 H) 3.20 (s, 2 H) 7.37 (s, 1 H)
7.56 (d, J=2.32
Hz, 1 H) 8.36 (d, J=6.95 Hz, 2 H) 8.72 (d, J=6.95 Hz, 2 H) 12.34 (s, 1 H)
49
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
7,7-diethyl-2-pyridin-4-yi-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) b ppm 0.83 (t, J=7.56 Hz, 6 H) 1.69 -1.89 (m, 4 H)
3.28 (d,
J=2.44 Hz, 2 H) 7.31 (s, 1 H) 7.59 (d, J=2.32 Hz, 1 H) 8.33 (d, J=6.71 Hz, 2
H) 8.71 (d, J=7.07
Hz, 2 H) 11.99 (s, 1 H)
6-(2-phenylethyl)-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-
one
h~ rochloride
1 H NMR (400 MHz, DMSO-D6) S ppm 1.77 - 2.03 (m, 2 H) 2.63 - 2.77 (m, 2 H)
2.85 (dd,
J=16.71, 9.76 Hz, 1 H) 3.05 (dd, J=16.10, 5.00 Hz, 1 H) 3.62 - 3.81 (m, 1 H)
7.25 (s, 5 H) 7.42
(s, 1 H) 7.58 (s, 1 H) 8.19 (d, J=6.10 Hz, 2 H) 8.70 (d, J=6.83 Hz, 2 H) 12.70
(s, 1 H)
6-methyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) ~ ppm 1.26 (d, J=6.46 Hz, 3 H) 2.63 - 2.73 (dd,
J=10.00,
16.34 Hz, 1 H) 3.01 (dd, J=16.40, 5.06 Hz, 1 H) 3.74 - 3.86 (m, 1 H) 7.28 (s,
1 H) 7.58 (d,
J=2.32 Hz, 1 H) 8.18 (d, J=6.22 Hz, 2 H) 8.70 (d, J=7.07 Hz, 2 H) 12.67 (s, 1
H)
7-cyclohexyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-cjeyridin-4-one
ESI (+) MS: m/z 296 (MH+).
3-methyl-2-pyridin-4-yt-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) b ppm 2.66 (s, 4 H) 2.90 (t, J=6.83 Hz, 3 H) 3.29 -
3.47 (m, 2
H) 7.24 (s, 1 H) 8.00 (d, J=6.95 Hz, 2 H) 8.71 (d, J=7.19 Hz, 2 H) 12.39 (s, 1
H)
2-(1 H-pyrrolo[2,3-b]pyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) 8 ppm 2.95 (t, J=6.71 Hz, 2H) 3.47 (t, J=6.71 Hz,
2H) 7.10 (s,
1 H9) 7.22 (bs, 1 H) 7.29 (s, 1 H) 7.61 (bd, 1 H) 7.71 (bt, 1 H) 8.38 (d, J=
6.10 Hz) 12.26 (bs, 1 W)
50
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
6-benzyl-3-methyl-2-pyridin-4-yl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-
one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) 5 ppm 2.66 (s, 3 H) 2.68 - 2.83 (m, 3 H) 3.02 (dd,
J=13.29,
5.12 Hz, 1 H) 3.82 - 3.95 (m, 1 H) 7.23 - 7.29 (m, 4 H) 7.31 - 7.38 (m, 2 H)
7.97 (d, J=7.19 Hz,
2 H) 8.70 (d, J=7.19 Hz, 2 H) 12.30 (s, 1 H)
6-isobutyl-3-methyl-2-pyridin-4-yl-1,5,6,T-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) b ppm 0.91 (dd, J=6.58, 10.48 Hz, 6H) 1.35 (m, 1 H)
1.52 (m,
id 1 H) 1.75 (m, 1 H) 2.66 (m, 4H) 3.02 (dd, J=5.12, 16.34 Hz, 1 H) 3.69 (m, 1
H) 7.20 (bs, 1 H)
7.99 (d, J=7.08 Hz, 2H) 1.86 (d, J=7.08 Hz, 2H) 12.36 (bs, 1 H)
By working in an analogous way and by starting from 2-bromo-1-(3-fluoropyridin-
4-yi)ethanone
hydrobromide and the suitable piperidine-dione derivative, the following
compounds were
prepared:
2-(3-fluoropyridin-4-yl)-7-isopropyl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-
c]pyridin-4-one
1 H NMR (400 MHz, DMSO-D6) 5 ppm 0.92 (d, J=6.83 Hz, 3 H) 0.95 (d, J=6.75 Hz,
3 H) 2.06
(m, 1 H) 2.72 (m, 1 H) 3.35 (m, 1 H) 3.51 (m, 1 H) 6.95 (t, J=2.93 Hz, 1 H)
7.04 (d, J=3.54 Hz,
1 H) 7.81 (d, J=5.12 Hz, 1 H) 7.81 (m, 1 H) 8.41 (m, 1 H) 8.56 (d, J=3.54 Hz,
1 H) 11.79 (s, 1
H)
ESI (+) MS: m/z 274 (MH+).
The racemate was subjected to chiral separation so to obtain the pure
enantiomers. Chiral
chromatography was pertormed on CHIRALPACK~ AS (5 x 50 cm). Mobile phase was n-
HexIEtOH/MeOH 75:18:7.
Analytical conditions: Chiralpack~ AS column, mobile phase n-Hex/EtOH/MeOH
70:15:15.
(7R or 7S)-2-(3-fluoropyridin-4-yl)-7-isopropyl-1,5,6,7-tetrahydro-4H-
pyrrolo[3,2-
c]pyridin-4-one
RT 6.2 min; e.e. 99.5%
51
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
(7R or 7S)-2-(3-fluoropvridin-4-yl)-7-isopropvi-1,5,6,7-tetrahydro-4H-
pvrraio[3,2
c]pyridin-4-one
RT 9.4 min; e.e. 90%
2-(3-fluoropyridin-4-yl)-6-isobutyl-1,5,6,7..tetrahydro-4H-pyrrolo[3,2-
c]pyridin 4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6): i5 ppm 0.91 (dd, J=6.46, 10.49 Hz, 6H) 1.38 (m, 1
H) 1.54 (m,
1 H) 1.76 (m, 1 H) 2.69 (dd, J=8.91, 16.47 Hz, 1 H) 3.03 (dd, J=5.37, 16.47
Hz, 1 H) 3.73 (m,
1 H) 7.12 (t, J=2.80 Hz, 1 H) 7.18 (bs, 1 H) 7.98 (dd, J=5.73, 7.20 Hz, 1 H)
8.51 (d, J=5.73 Hz,
1 h) 8.76 (d, J=4.39 Hz, 1 H)
The racemate was subjected to chiral separation so to obtain the pure
enantiomers. Chiral
chromatography was performed on CHIRALCELL° OJ (5 x 50 cm). Mobile
phase was
n-Hex/EtOH 80:20.
Analytical conditions: Chiralcell° OJ column, with precolumn, mobile
phase n-Hex/EtOH
80:20.
(6R or 6S)-2-(3-fluoropyridin-4-yl)-6-isobut rLl-1,5,6,7-tetrahydro-4H-
pyrrolo[3 2 c]p~rridin
4-ane hydrochloride
RT 8.3 min; e.e. 99.4%
(6R or 6S)-2-(3-fluoropyridin-4-yl)-6-isobutyl-1,5,6,7-tetrahvdro-4H-
pyrrolo[3,2-c]pyridin
4-one hydrochioride
RT 10.2 min; e.e. 95%
2-(3-fluoropyridin-4-y1)-7-isobutyl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2
cipyridin 4 one
1 H NMR (400 MHz, DMSO-D6) ~ ppm 0.93 (d, J=6.41 Hz, 3 H), 0.95 (d, J=6.45 Hz,
3 H), 1.48
- 1.71 (m, 3H), 3.02 (m, 1 H), 3.21 (m, 1 H), 3.51 (m, 1 H), 6.93 (m, 1 H),
7.07 (s, 1 H), 7.81 (m,
1 H), 8.41 (m, 1 H), 8.56 (d, J=3.41 Hz, 1 H), 11.75 (s, 1 H).
ESI (+) MS: m/z 288 (MH+).
52
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
The racemate, as Boc derivative, was subjected to chiral separation so to
obtain the. pure
enantiomers. Chiral chromatography was performed on CHIRALPACK~ AD (5 x 50
cm).
Mobile phase was n-Hex/EtOH 80:20.
Analytical conditions: Chiralpack~ AD column, mobile phase n-Hex/EtOH 85:15.
~7R or 7S)-2-(3-fluoropyridin-4-yl)-7-isobutyl-1,5,6,7-tetrahydro-4H-
p_yrrolo[3,2-c]pyridin-
4-one
(7R or 7S)-2-(3-fluoropyridin-4-yl)-7-isobutyt-1,5,6,7-tetrahydro-4H-
pyrrolo[3,2-c]pyridin-
4-one
2-(3-fluoropyridin-4-yl)-7-ethyl-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-clpyrldin-4-
one
1 H NMR (400 MHz, DMSO-D6) i5 ppm 0.96 (t, J=7.43 Hz, 3 H), 1.62 (m, 1 H),
1.80 (m, 1 H),
2.89 (m, 1 H), 3.25 (m, 1 H), 3.54 (m, 1 H), 6.94 (m, 1 H), 7.07 (s, 1 H),
7.80 (m, 1 H), 8.41 (m,
1 H), 8.55 (d, J=3.40 Hz, 1 H), 11.81 (s, 1 H)
ESI (+) MS: m/z 260 (MH+).
The racemate was subjected to chiral separation so to obtain the pure
enantiomers. Chiral
chromatography was performed on CHIRALPACK~ AD (5 x 50 cm). Mobile phase was
n-Hex/iPrOH/MeOH 80:5:15
Analytical conditions: Chiralpack~ AD column, mobile phase n-HexIEtOH 80:20.
(7R or 7S)-7-ethyl-2-(3-fluoropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo 3,2-
c]pyridin-4-
one
RT 9.4 min; e:e. 99.5%
(7R or 75)-7-ethyl-2-(3-fluoropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-
c]pyridin-4-
one
RT 10.6 min; e.e. 99.5%
2-(3-fluoropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-cjpyridin-4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) i5 ppm 2.91 (m, 2H) 3.41 (m, 2H) 7.08 (bs, 1 H)
7.19 (bs, 1 H)
7.90 (dd, J=5.60, 7.19 Hz, 1 H) 8.48 (d, J=5.00 Hz, 1 H) 8.70 (d; J=4.15 Hz, 1
H) 12.15 (bs, 1 H)
53
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
6-benzyl-2-(3-fluoropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-
4-one
hydrochloride
1 H NMR (400 MHz, DMSO-D6) i5 ppm 2.63 -3.13 (m, 4 H) 3.85 - 4.02 (m, 1 H)
7.10 - 7.15 (m,
1 H) 7.20 - 7.30 (m, 4 H) 7.32 - 7.38 (m, 2 H) 7.88 - 7.98 (m, 1 H) 8.50 (dd,
J=5.49, 2.68 Hz, 1
H) 8.76 (t, J=4.69 Hz, 1 H) 12.16 (s, 1 H)
By working in an analogous way and by starting from 2-bromo-1-(3-fluoropyridin-
4-yl)ethanone
hydrobromide and the N-protected (as Boc) piperidine-dione derivative, the
following
compounds were prepared:
tert-butyl 7-ethyl-2-(3-fluoropyridin-4-yl)-4-oxo-1,~4,6,7-tetrahydro-5N-
pyrrolo[3,2-
c]pyridine-5-carboxylate
1 H NMR (400 MHz, DMSO-D6) 8 ppm 0.99 (t, J=7.44 Hz, 3 H), 1.49 (s, 9H), 1.60
(m, 1 H),
1.81 (m, 1 H), 2.99 (m, 1 H), 3.91 (dd, J=4.27 Hz, J=13.17, 1 H), 4.07 (dd,
J=4.39 Hz, J=13.29,
1 H), 7.03 (m, 1 H), 7.81 (m, 1 H), 8.45 (m, 1 H), 8.60 (d, J=3.29 Hz, 1 H),
12.07 (s, 1 H).
ESI (+) MS: m/z 360 (MH+).
tert-butyl 7-isobutyl-2-(3-fluoropyridin-4-yl)-4-oxo-1,4,6,7-tetrahydro-5H-
pyrrolo[3,2-
c]pyridine-5-carboxylate
ESI (+) MS: m/z 388 (MH+).
Example 20
2-(2-imidazol-1-yl-pyridin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-
one
A mixture of 2-(2-chloro-pyridin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-
c]pyridin-4-one (200 mg,
0.81 mmol), and imidazole (332 mg, 4.88 mmol) was stirred at 250 °C.
After 4h the mixture
was cooled at room temperature and the crude residue purified by preparative
reverse phase
HPLC, yielding the title compound as a pale brown solid (200 mg, 88% yield).
'H-NMR 400MHz (DMSO-d6): i5 ppm 2.90 (t, J = 8.0 Hz , 2H), 3.45 (m, 2H), 7.09
(m, 1 H),
7.16 (m, 1 H), 7.31 (m, 1 H), 7.60 (m, 1 H), 8.00 (m, 1 H), 8.03 (m, 1 H),
8.41 (m, 1 H), 8.57 (m,
1 H), 11.99 (s, 1 H);
MS (ESI) 280 (M+H)''.
By analogous procedure the following compounds were obtained:
54
CA 02535125 2006-02-07
WO 2005/013986 PCT/EP2004/008811
2-(2-pyrrolidin-1-yl-pyridin-4-yl)-1 5,6,7-tetrahyd ro-pyrrolo[3,2-c]pyridin-4-
on a
' H-NMR 400MHz (DMSO-d6): b ppm 1.97 (m, 4H), 2.85 (m, 2H), 3.43 (m, 6H), 6.69
(m, 1 H),
6.82 (m, 1 H), 6.88 (m, 1 H), 6.99 (m, 1 H), 7.97 (m, 1 H), 11.76 (s, 1 H);
MS (ESI) 283 (M+H)+.
2-(2-pyrazol-1-yl-pyridin-4-yl)-1,5,6,7-tetrahydro-pyrroio[3,2-c)pyridin-4-one
'H-NMR 400MHz (DMSO-d6): 8 ppm 2.87 (t, J = 8.0 Hz , 2H), 3.43 (m, 2H), 6.61
(m, 1 H),
7.09 (m, 2H), 7.62 (m, 1 H), 7.87 (m, 1 H), 8.18 (m, 1 H), 8.36 (m, 1 H), 8.63
(m, 1 H), 12.20 (s,
1 H);
MS (ESI) 280 (M+H)+.
2-[2-(3-amino-pyrrolidln-1-yl)-pyridin-4-yl]-1,5,fi,7-tetrahydro-pyrrolo[3,2-
c)pyridin-4-one
'H-NMR 400MHz (DMSO-d6): b ppm 1.77 (m, 1 H), 2.10 (m, 1 H), 2.85 (t, J = 8.0
Hz , 2H),
3.12 (m, 1 H), 3.42 (m, 4H), 3.57 (m, 2H), 6.65 (m, 1 H), 6.80 (m, 1 H), 6.86
(m, 1 H), 6.98 (s,
1 H), 7.98 (m, 1 H), 11.76 (s, 1 H);
MS (ESI) 298 (M+H)'.
Example 21
2-(2-cyclopentylamino-pyridin-4-~)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-
one
2-(2-Chloro-pyridin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one (100
mg, 0.40 mmol)
and cyclopentylamine (2.5 mL) were placed in a process vial which was sealed
with a teflon
septum and then placed in the microwave cavity. The reaction mixture was
stirred for 10 min
at 250°C, thereafter diluted with ethyl acetate and washed with brine.
The organic phase was
dried (MgS04), and the solvent was evaporated. The residue was purified by
flash
chromatography (DCM-MeOH-30% NH40W, 95:5:0.5) to give the product as a white
solid (42
mg, 35% yield).
'H NMR (400 MHz, DMSO-d6) b ppm 1.38 -1.76 (m, 6 H), 1.89 - 2.01 (m, 2 H),
2.83 (t, J=6.89
Hz, 2 H), 3.36 - 3.46 (m, 2 H), 3.99 - 4.17 (m, 1 H), 6.32 (d, J=4.51 Hz, 1
H), 6.63 (s, 1 H),
6.71 - 6.77 (m, 2 H), 6.99 (t, J=2.38 Hz, 1 H), 7.91 (d, J=5.37 Hz, 1 H),
11.71 (s, 1 H).
